



(11) **EP 1 808 182 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
18.07.2007 Bulletin 2007/29

(21) Application number: **07003497.0**

(22) Date of filing: **28.04.2000**

(51) Int Cl.:
A61K 48/00 (2006.01) **C07H 21/04** (2006.01)
C07K 14/00 (2006.01) **C07K 16/00** (2006.01)
C12N 15/63 (2006.01) **C12N 15/85** (2006.01)
C12N 15/86 (2006.01)

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **30.04.1999 US 132021**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
00928626.1 / 1 181 056

(71) Applicant: **EMORY UNIVERSITY**
Atlanta, GA 30322 (US)

(72) Inventors:
• **Boden, Scott, D.**
Atlanta, GA 30345 (US)

• **Hair, Gregory, A.**
Lilburn, GA 30047 (US)

(74) Representative: **Grünecker, Kinkeldey,**
Stockmair & Schwanhäusser
Anwaltssozietät
Maximilianstrasse 58
80538 München (DE)

Remarks:

This application was filed on 20 - 02 - 2007 as a
divisional application to the application mentioned
under INID code 62.

(54) **Lim mineralization protein splice variants**

(57) The present invention is directed to isolated nucleic acid molecules that encode LIM mineralization protein, or LMP. The invention further provides vectors comprising nucleotide sequences that encode LMP, as well as host cells comprising those vectors. Moreover, the present invention relates to methods of inducing bone formation by transfecting osteogenic precursor cells with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein. The transfection may occur ex vivo or in vivo by direct injection of virus or naked plasmid DNA. In a particular embodi-

ment, the invention provides a method of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine. Finally, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention.

EP 1 808 182 A1

Description

BACKGROUND OF THE INVENTION

1. Field of the Invention

[0001] The field of the invention relates generally to osteogenic cells and the formation of bone and boney tissue in mammalian species. Specifically, the invention concerns a novel family of proteins, and nucleic acids encoding those proteins, that enhances the efficacy of bone mineralization *in vitro* and *in vivo*. The invention provides methods for treating a variety of pathological conditions associated with bone and boney tissue, such as, for example, spine fusion, fracture repair and osteoporosis.

2. Description of the Related Art

[0002] Osteoblasts are thought to differentiate from pluripotent mesenchymal stem cells. The maturation of an osteoblast results in the secretion of an extracellular matrix which can mineralize and form bone. The regulation of this complex process is not well understood but is thought to involve a group of signaling glycoproteins known as bone morphogenetic proteins (BMPs). These proteins have been shown to be involved with embryonic dorsal-ventral patterning, limb bud development, and fracture repair in adult animals. B. L. Hogan, *Genes & Develop.*, 10:1580 (1996). This group of transforming growth factor-beta superfamily secreted proteins has a spectrum of activities in a variety of cell types at different stages of differentiation; differences in physiological activity between these closely related molecules have not been clarified. D. M. Kingsley, *Trends Genet.*, 10:16 (1994).

[0003] To better discern the unique physiological role of different BMP signaling proteins, we recently compared the potency of BMP-6 with that of BMP-2 and BMP-4, for inducing rat calvarial osteoblast differentiation. Boden et al., *Endocrinology*, 137:3401 (1996). We studied this process in first passage (secondary) cultures of fetal rat calvaria that require BMP or glucocorticoid for initiation of differentiation. In this model of membranous bone formation, glucocorticoid (GC) or a BMP will initiate differentiation to mineralized bone nodules capable of secreting osteocalcin, the osteoblast-specific protein. This secondary culture system is distinct from primary rat osteoblast cultures which undergo spontaneous differentiation. In this secondary system, glucocorticoid resulted in a ten-fold induction of BMP-6 mRNA and protein expression which was responsible for the enhancement of osteoblast differentiation. Boden et al., *Endocrinology*, 138:2920 (1997).

[0004] In addition to extracellular signals, such as the BMPs, intracellular signals or regulatory molecules may also play a role in the cascade of events leading to formation of new bone. One broad class of intracellular regulatory molecules are the LIM proteins, which are so named because they possess a characteristic structural motif known as the LIM domain. The LIM domain is a cysteine-rich structural motif composed of two special zinc fingers that are joined by a 2-amino acid spacer. Some proteins have only LIM domains, while others contain a variety of additional functional domains. LIM proteins form a diverse group, which includes transcription factors and cytoskeletal proteins. The primary role of LIM domains appears to be in mediating protein-protein interactions, through the formation of dimers with identical or different LIM domains, or by binding distinct proteins.

[0005] In LIM homeodomain proteins, that is, proteins having both LIM domains and a homeodomain sequence, the LIM domains function as negative regulatory elements. LIM homeodomain proteins are involved in the control of cell lineage determination and the regulation of differentiation, although LIM-only proteins may have similar roles. LIM-only proteins are also implicated in the control of cell proliferation since several genes encoding such proteins are associated with oncogenic chromosome translocations.

[0006] Humans and other mammalian species are prone to diseases or injuries that require the processes of bone repair and/or regeneration. For example, treatment of fractures would be improved by new treatment regimens that could stimulate the natural bone repair mechanisms, thereby reducing the time required for the fractured bone to heal. In another example, individuals afflicted with systemic bone disorders, such as osteoporosis, would benefit from treatment regimens that would results in systemic formation of new bone. Such treatment regimens would reduce the incidence of fractures arising from the loss of bone mass that is a characteristic of this disease.

[0007] For at least these reasons, extracellular factors, such as the BMPs, have been investigated for the purpose of using them to stimulate formation of new bone *in vivo*. Despite the early successes achieved with BMPs and other extracellular signalling molecules, their use entails a number of disadvantages. For example, relatively large doses of purified BMPs are required to enhance the production of new bone, thereby increasing the expense of such treatment methods. Furthermore, extracellular proteins are susceptible to degradation following their introduction into a host animal. In addition, because they are typically immunogenic, the possibility of stimulating an immune response to the administered proteins is ever present.

[0008] Due to such concerns, it would be desirable to have available treatment regimens that use an intracellular

signalling molecule to induce new bone formation. Advances in the field of gene therapy now make it possible to introduce into osteogenic precursor cells, that is, cells involved in bone formation, or peripheral blood leukocytes, nucleotide fragments encoding intracellular signals that form part of the bone formation process. Gene therapy for bone formation offers a number of potential advantages: (1) lower production costs; (2) greater efficacy, compared to extracellular treatment regimens, due to the ability to achieve prolonged expression of the intracellular signal; (3) it would by-pass the possibility that treatment with extracellular signals might be hampered due to the presence of limiting numbers of receptors for those signals; (4) it permits the delivery of transfected potential osteoprogenitor cells directly to the site where localized bone formation is required; and (5) it would permit systemic bone formation, thereby providing a treatment regimen for osteoporosis and other metabolic bone diseases.

SUMMARY OF THE INVENTION

[0009] The present invention seeks to overcome the drawbacks in the prior art by providing novel compositions and methods for inducing bone formation using an intracellular signalling molecule that participates early in the cascade of events that leads to bone formation. Applicants have discovered 10-4/RLMP (SEQ ID NO: 1, SEQ ID NO: 2), a novel LIM gene with a sequence originally isolated from stimulated rat calvarial osteoblast cultures. The gene has been cloned, sequenced and assayed for its ability to enhance the efficacy of bone mineralization *in vitro*. The protein RLMP affects mineralization of bone matrix as well as differentiation of cells into the osteoblast lineage. Unlike other known cytokines, for example, BMPs, RLMP is not a secreted protein, but is instead an intracellular signaling molecule. This feature has the advantage of providing intracellular signaling amplification as well as easier assessment of transfected cells. It is also suitable for more efficient and specific *in vivo* applications. Suitable clinical applications include enhancement of bone repair in fractures, bone defects, bone grafting, and normal homeostasis in patients presenting with osteoporosis.

[0010] Applicants have also cloned, sequenced and deduced the amino acid sequence of a corresponding human protein, named human LMP-1. The human protein demonstrates enhanced efficacy of bone mineralization *in vitro* and *in vivo*.

[0011] In addition, the applicants have characterized a truncated (short) version of LMP-1, termed HLMP-1 s. This short version resulted from a point mutation in one source of a cDNA clone, providing a stop codon which truncated the protein. The short version (LMP-1s) is fully functional when expressed in cell culture and *in vivo*.

[0012] Using PCR analysis of human heart cDNA library, Applicants have identified two alternative splice variants (referred to as HLMP-2 and HLMP-3) that differ from HLMP-1 in a region between base pairs 325 and 444 in the nucleotide sequence encoding HLMP-1. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. Compared to HLMP-1, the nucleotide sequence encoding HLMP-3 has no deletions, but it does have the same 17 base pairs as HLMP-2, which are inserted at position 444 in the HLMP-1 sequence.

[0013] Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the methods and compositions of matter particularly pointed out in the written description and claims hereof.

[0014] In one broad aspect, the invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding any LIM mineralization protein, wherein the nucleic acid molecule hybridizes under standard conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 25, and wherein the molecule hybridizes under highly stringent conditions to a nucleic acid molecule complementary to the full length of SEQ. ID NO: 26. In a specific aspect, the isolated nucleic acid molecule encodes HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3. In addition, the invention is directed to vectors comprising these nucleic acid molecules, as well as host cells comprising the vectors. In another specific aspect, the invention relates to the proteins themselves.

[0015] In a second broad aspect, the invention relates to antibody that is specific for LIM mineralization protein, including HLMP-1, HLMP-1 s, RLMP, HLMP-2, and HLMP-3. In one specific aspect, the antibody is a polyclonal antibody. In another specific aspect, the antibody is a monoclonal antibody.

[0016] In a third broad aspect, the invention relates to method of inducing bone formation wherein osteogenic precursor cells are transfected with an isolated nucleic acid molecule comprising a nucleotide sequence encoding LIM mineralization protein. In one specific aspect, the isolated nucleic acid molecule is in a vector, which may be a plasmid or a virus, such as adenovirus or retrovirus. The transfection may occur *ex vivo* or *in vivo* by direct injection of the isolated nucleic acid molecule. The transfected isolated nucleic acid molecule may encode HLMP-1, HLMP-1s, RLMP, HLMP-2, or HLMP-3.

[0017] In a further aspect, the invention relates to methods of fusing a spine by transfecting osteogenic precursor cells with an isolated nucleic acid molecule having a nucleotide sequence encoding LIM mineralization protein, admixing the transfected osteogenic precursor cells with a matrix and contacting the matrix with the spine.

[0018] In yet another aspect, the invention relates to methods for inducing systemic bone formation by stable transfection of host cells with the vectors of the invention.

[0019] It is to be understood that both the foregoing general description and the following detailed description are

exemplary and explanatory and are intended to provide further explanation of the invention as claimed.

ABBREVIATIONS AND DEFINITIONS

[0020]

BMP	Bone Morphogenetic Protein
HLMP-1	Human LMP-1, also designated as Human LIM Protein or HLMP
HLMP-1s	Human LMP-1 Short (truncated) protein
HLMPU	Human LIM Protein Unique Region
LMP	LIM mineralization protein
MEM	Minimal essential medium
Trm	Triamcinolone
-GlyP	Beta-glycerolphosphate
RACE	Rapid Amplification of cDNA Ends
RLMP	Rat LIM mineralization protein, also designated as RLMP-1
RLMPU	Rat LIM Protein Unique Region
RNasin	RNase inhibitor
ROB	Rat Osteoblast
10-4	Clone containing cDNA sequence for RLMP (SEQ ID NO: 2)
UTR	Untranslated Region
HLMP-2	Human LMP Splice Variant 2
HLMP-3	Human LMP Splice Variant 3

DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention relates to novel mammalian LIM proteins, herein designated LIM mineralization proteins, or LMP. The invention relates more particularly to human LMP, known as HLMP or HLMP-1, or alternative splice variants of human LMP, which are known as HLMP-2 or HLMP-3. The applicants have discovered that these proteins enhance bone mineralization in mammalian cells grown *in vitro*. When produced in mammals, LMP also induces bone formation *in vivo*.

[0022] *Ex vivo* transfection of bone marrow cells, osteogenic precursor cells, peripheral blood leukocytes, or mesenchymal stem cells with nucleic acid that encodes LMP or HLMP, followed by reimplantation of the transfected cells in the donor, is suitable for treating a variety of bone-related disorders or injuries. For example, one can use this method to: augment long bone fracture repair; generate bone in segmental defects; provide a bone graft substitute for fractures; facilitate tumor reconstruction or spine fusion; and provide a local treatment (by injection) for weak or osteoporotic bone, such as in osteoporosis of the hip, vertebrae, or wrist. Transfection with LMP or HLMP-encoding nucleic acid is also useful in: the percutaneous injection of transfected marrow cells to accelerate the repair of fractured long bones; treatment of delayed union or non-unions of long bone fractures or pseudoarthrosis of spine fusions; and for inducing new bone formation in avascular necrosis of the hip or knee.

[0023] In addition to *ex vivo*-based methods of gene therapy, transfection of a recombinant DNA vector comprising a nucleic acid sequence that encodes LMP or HLMP can be accomplished *in vivo*. When a DNA fragment that encodes LMP or HLMP is inserted into an appropriate viral vector, for example, an adenovirus vector, the viral construct can be injected directly into a body site where endochondral bone formation is desired. By using a direct, percutaneous injection to introduce the LMP or HLMP sequence stimulation of bone formation can be accomplished without the need for surgical intervention either to obtain bone marrow cells (to transfect *ex vivo*) or to reimplant them into the patient at the site where new bone is required. Alden *et al.*, Neurosurgical Focus (1998), have demonstrated the utility of a direct injection method of gene therapy using a cDNA that encodes BMP-2, which was cloned into an adenovirus vector.

[0024] It is also possible to carry out *in vivo* gene therapy by directly injecting into an appropriate body site, a naked, that is, unencapsulated, recombinant plasmid comprising a nucleic acid sequence that encodes HLMP. In this embodiment of the invention, transfection occurs when the naked plasmid DNA is taken up, or internalized, by the appropriate target cells, which have been described. As in the case of *in vivo* gene therapy using a viral construct, direct injection

of naked plasmid DNA offers the advantage that little or no surgical intervention is required. Direct gene therapy, using naked plasmid DNA that encodes the endothelial cell mitogen VEGF (vascular endothelial growth factor), has been successfully demonstrated in human patients. Baumgartner et al., *Circulation*, 97(12):1114-23 (1998).

[0025] By using an adenovirus vector to deliver LMP into osteogenic cells, transient expression of LMP is achieved. This occurs because adenovirus does not incorporate into the genome of target cells that are transfected. Transient expression of LMP, that is, expression that occurs during the lifetime of the transfected target cells, is sufficient to achieve the objects of the invention. Stable expression of LMP, however, can occur when a vector that incorporates into the genome of the target cell is used as a delivery vehicle. Retrovirus-based vectors, for example, are suitable for this purpose.

[0026] Stable expression of LMP is particularly useful for treating various systemic bone-related disorders, such as osteoporosis and osteogenesis imperfecta. For this embodiment of the invention, in addition to using a vector that integrates into the genome of the target cell to deliver an LMP-encoding nucleotide sequence into target cells, LMP expression is placed under the control of a regulatable promoter. For example, a promoter that is turned on by exposure to an exogenous inducing agent, such as tetracycline, is suitable. Using this approach, one can stimulate formation of new bone on a systemic basis by administering an effective amount of the exogenous inducing agent. Once a sufficient quantity of bone mass is achieved, administration of the exogenous inducing agent is discontinued. This process may be repeated as needed to replace bone mass lost, for example, as a consequence of osteoporosis.

[0027] Antibodies specific for HLMP are particularly suitable for use in methods for assaying the osteoinductive, that is, bone-forming, potential of patient cells. In this way one can identify patients at risk for slow or poor healing of bone repair. Also, HLMP-specific antibodies are suitable for use in marker assays to identify risk factors in bone degenerative diseases, such as, for example, osteoporosis.

[0028] Following well known and conventional methods, the genes of the present invention are prepared by ligation of nucleic acid segments that encode LMP to other nucleic acid sequences, such as cloning and/or expression vectors. Methods needed to construct and analyze these recombinant vectors, for example, restriction endonuclease digests, cloning protocols, mutagenesis, organic synthesis of oligonucleotides and DNA sequencing, have been described. For DNA sequencing DNA, the dideoxymethod is the preferred.

[0029] Many treatises on recombinant DNA methods have been published, including Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, 2nd edition (1988), Davis et al., *Basic Methods in Molecular Biology*, Elsevier (1986), and Ausubel et al., *Current Protocols in Molecular Biology*, Wiley Interscience (1988). These reference manuals are specifically incorporated by reference herein.

[0030] Primer-directed amplification of DNA or cDNA is a common step in the expression of the genes of this invention. It is typically performed by the polymerase chain reaction (PCR). PCR is described in U.S. Patent No. 4,800,159 to Mullis et al, and other published sources. The basic principle of PCR is the exponential replication of a DNA sequence by successive cycles of primer extension. The extension products of one primer, when hybridized to another primer, becomes a template for the synthesis of another nucleic acid molecule. The primer-template complexes act as substrate for DNA polymerase, which in performing its replication function, extends the primers. The conventional enzyme for PCR applications is the thermostable DNA polymerase isolated from *Thermus aquaticus*, or Taq DNA polymerase.

[0031] Numerous variations of the basic PCR method exist, and a particular procedure of choice in any given step needed to construct the recombinant vectors of this invention is readily performed by a skilled artisan. For example, to measure cellular expression of 10-4/RLMP, RNA is extracted and reverse transcribed under standard and well known procedures. The resulting cDNA is then analyzed for the appropriate mRNA sequence by PCR.

[0032] The gene encoding the LIM mineralization protein is expressed in an expression vector in a recombinant expression system. Of course, the constructed sequence need not be the same as the original, or its complimentary sequence, but instead may be any sequence determined by the degeneracy of the DNA code that nonetheless expresses an LMP having bone forming activity. Conservative amino acid substitutions, or other modifications, such as the occurrence of an amino-terminal methionine residue, may also be employed.

[0033] A ribosome binding site active in the host expression system of choice is ligated to the 5' end of the chimeric LMP coding sequence, forming a synthetic gene. The synthetic gene can be inserted into any one of a large variety of vectors for expression by ligating to an appropriately linearized plasmid. A regulatable promoter, for example, the *E. coli* lac promoter, is also suitable for the expression of the chimeric coding sequences. Other suitable regulatable promoters include trp, tac, recA, T7 and lambda promoters.

[0034] DNA encoding LMP is transfected into recipient cells by one of several standard published procedures, for example, calcium phosphate precipitation, DEAE-Dextran, electroporation or protoplast fusion, to form stable transformants. Calcium phosphate precipitation is preferred, particularly when performed as follows.

[0035] DNAs are coprecipitated with calcium phosphate according to the method of Graham and Van Der, *Virology*, 52:456 (1973), before transfer into cells. An aliquot of 40-50 g of DNA, with salmon sperm or calf thymus DNA as a carrier, is used for 0.5×10^8 cells plated on a 100 mm dish. The DNA is mixed with 0.5 ml of 2X Hepes solution (280 mM NaCl, 50 mM Hepes and 1.5 mM Na_2HPO_4 , pH 7.0), to which an equal volume of 2x CaCl_2 (250 mM CaCl_2 and 10 mM Hepes, pH 7.0) is added. A white granular precipitate, appearing after 30-40 minutes, is evenly distributed dropwise on

the cells, which are allowed to incubate for 4-16 hours at 37°C. The medium is removed and the cells shocked with 15% glycerol in PBS for 3 minutes. After removing the glycerol, the cells are fed with Dulbecco's Minimal Essential Medium (DMEM) containing 10% fetal bovine serum.

[0036] DNA can also be transfected using: the DEAE-Dextran methods of Kimura et al., *Virology*, 49:394 (1972) and Sompayrac et al., *Proc. Natl. Acad. Sci. USA*, 78:7575 (1981); the electroporation method of Potter, *Proc. Natl. Acad. Sci. USA*, 81:7161 (1984); and the protoplast fusion method of Sandri-Goddin et al., *Molec. Cell.-Biol.*, 1:743 (1981).

[0037] Phosphoramidite chemistry in solid phase is the preferred method for the organic synthesis of oligodeoxynucleotides and polydeoxynucleotides. In addition, many other organic synthesis methods are available. Those methods are readily adapted by those skilled in the art to the particular sequences of the invention.

[0038] The present invention also includes nucleic acid molecules that hybridize under standard conditions to any of the nucleic acid sequences encoding the LIM mineralization proteins of the invention. "Standard hybridization conditions" will vary with the size of the probe, the background and the concentration of the nucleic acid reagents, as well as the type of hybridization, for example, *in situ*, Southern blot, or hybridization of DNA-RNA hybrids (Northern blot). The determination of "standard hybridization conditions" is within the level of skill in the art. For example, see U.S. Patent 5,580,775 to Freneau et al., herein incorporated by reference for this purpose. See also, Southern, E. M., *J. Mol. Biol.*, 98:503 (1975), Alwine et al., *Meth. Enzymol.*, 68:220 (1979), and Sambrook et al., *Molecular Cloning: A laboratory Manual*, 2nd edition, pp. 7.19-7.50, Cold Spring Harbor Press (1989).

[0039] One preferred set of standard hybridization conditions involves a blot that is prehybridized at 42°C for 2 hours in 50% formamide, 5X SSPE (150 nM NaCl, 10 mM Na H₂PO₄ [pH 7.4], 1 mM EDTA [pH 8.0]), 5X Denhardt's solution (20 mg Ficoll, 20 mg polyvinylpyrrolidone and 20 mg BSA per 100 ml water), 10% dextran sulphate, 1% SDS and 100 g/ml salmon sperm DNA. A ³²P-labelled cDNA probe is added, and hybridization is continued for 14 hours. Afterward, the blot is washed twice with 2X SSPE, 0.1% SDS for 20 minutes at 22°C, followed by a 1 hour wash at 65°C in 0.1X SSPE, 0.1 %SDS. The blot is then dried and exposed to x-ray film for 5 days in the presence of an intensifying screen.

[0040] Under "highly stringent conditions," a probe will hybridize to its target sequence if those two sequences are substantially identical. As in the case of standard hybridization conditions, one of skill in the art can, given the level of skill in the art and the nature of the particular experiment, determine the conditions under which only substantially identical sequences will hybridize.

[0041] Another aspect of the invention includes the proteins encoded by the nucleic acid sequences. In still another embodiment, the invention relates to the identification of such proteins based on anti-LMP antibodies. In this embodiment, protein samples are prepared for Western blot analysis by lysing cells and separating the proteins by SDS-PAGE. The proteins are transferred to nitrocellulose by electroblotting as described by Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley and Sons (1987). After blocking the filter with instant nonfat dry milk (1 gm in 100 ml PBS), anti-LMP antibody is added to the filter and incubated for 1 hour at room temperature. The filter is washed thoroughly with phosphate buffered saline (PBS) and incubated with horseradish peroxidase (HRPO)-antibody conjugate for 1 hour at room temperature. The filter is again washed thoroughly with PBS and the antigen bands are identified by adding diaminobenzidine (DAB).

[0042] Monospecific antibodies are the reagent of choice in the present invention, and are specifically used to analyze patient cells for specific characteristics associated with the expression of LMP. "Monospecific antibody" as used herein is defined as a single antibody species or multiple antibody species with homogenous binding characteristics for LMP. "Homogeneous binding" as used herein refers to the ability of the antibody species to bind to a specific antigen or epitope, such as those associated with LMP, as described above. Monospecific antibodies to LMP are purified from mammalian antisera containing antibodies reactive against LMP or are prepared as monoclonal antibodies reactive with LMP using the technique of Kohler and Milstein, *Nature*, 256:495-97 (1975). The LMP specific antibodies are raised by immunizing animals such as, for example, mice, rats, guinea pigs, rabbits, goats or horses, with an appropriate concentration of LMP either with or without an immune adjuvant.

[0043] In this process, preimmune serum is collected prior to the first immunization. Each animal receives between about 0.1 mg and about 1000 mg of LMP associated with an acceptable immune adjuvant, if desired. Such acceptable adjuvants include, but are not limited to, Freund's complete, Freund's incomplete, alum-precipitate, water in oil emulsion containing *Corynebacterium parvum* and tRNA adjuvants. The initial immunization consists of LMP in, preferably, Freund's complete adjuvant injected at multiple sites either subcutaneously (SC), intraperitoneally (IP) or both. Each animal is bled at regular intervals, preferably weekly, to determine antibody titer. The animals may or may not receive booster injections following the initial immunization. Those animals receiving booster injections are generally given an equal amount of the antigen in Freund's incomplete adjuvant by the same route. Booster injections are given at about three week intervals until maximal titers are obtained. At about 7 days after each booster immunization or about weekly after a single immunization, the animals are bled, the serum collected, and aliquots are stored at about -20° C.

[0044] Monoclonal antibodies (mAb) reactive with LMP are prepared by immunizing inbred mice, preferably Balb/c mice, with LMP. The mice are immunized by the IP or SC route with about 0.1 mg to about 10 mg, preferably about 1 mg, of LMP in about 0.5 ml buffer or saline incorporated in an equal volume of an acceptable adjuvant, as discussed

above. Freund's complete adjuvant is preferred. The mice receive an initial immunization on day 0 and are rested for about 3-30 weeks. Immunized mice are given one or more booster immunizations of about 0.1 to about 10 mg of LMP in a buffer solution such as phosphate buffered saline by the intravenous (IV) route. Lymphocytes from antibody-positive mice, preferably splenic lymphocytes, are obtained by removing the spleens from immunized mice by standard procedures known in the art. Hybridoma cells are produced by mixing the splenic lymphocytes with an appropriate fusion partner, preferably myeloma cells, under conditions which will allow the formation of stable hybridomas. Fusion partners may include, but are not limited to: mouse myelomas P3/NS1/Ag 4-1; MPC-11; S-194 and Sp 2/0, with Sp 2/0 being preferred. The antibody producing cells and myeloma cells are fused in polyethylene glycol, about 1000 mol. wt., at concentrations from about 30% to about 50%. Fused hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in supplemented Dulbecco's Modified Eagles Medium (DMEM) by procedures known in the art. Supernatant fluids are collected from growth positive wells on about days 14, 18, and 21, and are screened for antibody production by an immunoassay such as solid phase immunoradioassay (SPIRA) using LMP as the antigen. The culture fluids are also tested in the Ouchterlony precipitation assay to determine the isotype of the mAb. Hybridoma cells from antibody positive wells are cloned by a technique such as the soft agar technique of MacPherson, "Soft Agar Techniques", in Tissue Culture Methods and Applications, Kruse and Paterson (eds.), Academic Press (1973). See, also, Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Laboratory (1988).

[0045] Monoclonal antibodies may also be produced *in vivo* by injection of pristane-primed Balb/c mice, approximately 0.5 ml per mouse, with about 2×10^6 to about 6×10^6 hybridoma cells about 4 days after priming. Ascites fluid is collected at approximately 8-12 days after cell transfer and the monoclonal antibodies are purified by techniques known in the art.

[0046] *In vitro* production in anti-LMP mAb is carried out by growing the hybridoma cell line in DMEM containing about 2% fetal calf serum to obtain sufficient quantities of the specific mAb. The mAb are purified by techniques known in the art.

[0047] Antibody titers of ascites or hybridoma culture fluids are determined by various serological or immunological assays, which include, but are not limited to, precipitation, passive agglutination, enzyme-linked immunosorbent antibody (ELISA) technique and radioimmunoassay (RIA) techniques. Similar assays are used to detect the presence of the LMP in body fluids or tissue and cell extracts.

[0048] It is readily apparent to those skilled in the art that the above described methods for producing monospecific antibodies may be utilized to produce antibodies specific for polypeptide fragments of LMP, full-length nascent LMP polypeptide, or variants or alleles thereof.

[0049] In another embodiment, the invention is directed to alternative splice variants of HLMP-1. PCR analysis of human heart cDNA revealed mRNA for two HLMP alternative splice variants, named HLMP-2 and HLMP-3, that differ from HLMP-1 in a region between base pairs 325 and 444 in the hLMP-1 sequence. The HLMP-2 sequence has a 119 base pair deletion and an insertion of 17 base pairs in this region. These changes preserve the reading frame, resulting in a 423 amino acid protein, which compared to HLMP-1, has a net loss of 34 amino acids (40 amino acids deleted plus 6 inserted amino acids). HLMP-2 contains the c-terminal LIM domains that are present in HLMP-1.

[0050] Compared to HLMP-1, HLMP-3 has no deletions, but it does have the same 17 base pair insertion at position 444. This insertion shifts the reading frame, causing a stop codon at base pairs 459-461. As a result, HLMP-3 encodes a protein of 153 amino acids. This protein lacks the c-terminal LIM domains that are present in HLMP-1 and HLMP-2. The predicted size of the proteins encoded by HLMP-2 and HLMP-3 was confirmed by western blot analysis.

[0051] PCR analysis of the tissue distribution of the three splice variants revealed that they are differentially expressed, with specific isoforms predominating in different tissues. HLMP-1 is apparently the predominant form expressed in leukocytes, spleen, lung, placenta, and fetal liver. HLMP-2 appears to be the predominant isoform in skeletal muscle, bone marrow, and heart tissue. HLMP-3, however, was not the predominant isoform in any tissue examined.

[0052] Overexpression of HLMP-3 in secondary rat osteoblast cultures induced bone nodule formation (287 ± 56) similar to the effect seen for glucocorticoid (272 ± 7) and HLMP-1 (232 ± 200). Since HLMP-3 lacks the C-terminal LIM domains, these regions are not required for osteoinductive activity. Overexpression of HLMP-2, however, did not induce nodule formation (11 ± 3). These data suggest that the amino acids encoded by the deleted 119 base pairs are necessary for osteoinduction. The data also suggest that the distribution of HLMP splice variants may be important for tissue-specific function. Surprisingly, we have shown that HLMP-2 inhibits steroid-induced osteoblast formation in secondary rat osteoblast cultures. Therefore, HLMP-2 will have therapeutic utility in clinical situations where bone formation is not desirable.

[0053] On July 22, 1997, a sample of 10-4/RLMP in a vector designated pCMV2/RLMP (which is vector pRc/CMV2 with insert 10-4 clone/RLMP) was deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, MD 20852. The culture accession number for that deposit is 209153. On March 19, 1998, a sample of the vector pHis-A with insert HLPM-1s was deposited at the American Type Culture Collection ("ATCC"). The culture accession number for that deposit is 209698. On April 14, 2000, samples of plasmids pHAhLMP-2 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-2) and pHAhLMP-3 (vector pHisA with cDNA insert derived from human heart muscle cDNA with HLMP-3) were deposited with the ATCC, 10801 University Blvd., Manassas, VA, 20110-2209, USA, under the conditions of the Budapest treaty. The accession numbers for these deposits are PTA-

1698 and PTA-1699, respectively. These deposits, as required by the Budapest Treaty, will be maintained in the ATCC for at least 30 years and will be made available to the public upon the grant of a patent disclosing them. It should be understood that the availability of a deposit does not constitute a license to practice the subject invention in derogation of patent rights granted by government action.

[0054] In assessing the nucleic acids, proteins, or antibodies of the invention, enzyme assays, protein purification, and other conventional biochemical methods are employed. DNA and RNA are analyzed by Southern blotting and Northern blotting techniques, respectively. Typically, the samples analyzed are size fractionated by gel electrophoresis. The DNA or RNA in the gels are then transferred to nitrocellulose or nylon membranes. The blots, which are replicas of sample patterns in the gels, were then hybridized with probes. Typically, the probes are radiolabelled, preferably with ^{32}P , although one could label the probes with other signal-generating molecules known to those in the art. Specific bands of interest can then be visualized by detection systems, such as autoradiography.

[0055] For purposes of illustrating preferred embodiments of the present invention, the following, non-limiting examples are included. These results demonstrate the feasibility of inducing or enhancing the formation of bone using the LIM mineralization proteins of the invention, and the isolated nucleic acid molecules encoding those proteins.

Example 1: Calvarial Cell Culture

[0056] Rat calvarial cells, also known as rat osteoblasts ("ROB"), were obtained from 20-day pre-parturition rats as previously described. Boden et al., *Endocrinology*, 137(8):3401-07 (1996). Primary cultures were grown to confluence (7 days), trypsinized, and passed into 6-well plates (1×10^5 cells/35 mm well) as first subculture cells. The subculture cells, which were confluent at day 0, were grown for an additional 7 days. Beginning on day 0, media were changed and treatments (Trm and/or BMPs) were applied, under a laminar flow hood, every 3 or 4 days. The standard culture protocol was as follows: days 1-7, MEM, 10% FBS, 50 g/ml ascorbic acid, $\pm$ stimulus; days 8-14, BGJb medium, 10% FBS, 5mM -GlyP (as a source of inorganic phosphate to permit mineralization). Endpoint analysis of bone nodule formation and osteocalcin secretion was performed at day 14. The dose of BMP was chosen as 50 ng/ml based on pilot experiments in this system that demonstrated a mid-range effect on the dose-response curve for all BMPs studied.

EXAMPLE 2: Antisense Treatment and Cell Culture

[0057] To explore the potential functional role of LMP-1 during membranous bone formation, we synthesized an antisense oligonucleotide to block LMP-1 mRNA translation and treated secondary osteoblast cultures that were undergoing differentiation initiated by glucocorticoid. Inhibition of RLMP expression was accomplished with a highly specific antisense oligonucleotide (having no significant homologies to known rat sequences) corresponding to a 25 bp sequence spanning the putative translational start site (SEQ ID NO: 42). Control cultures either did not receive oligonucleotide or they received sense oligonucleotide. Experiments were performed in the presence (preincubation) and absence of lipofectamine. Briefly, 22 g of sense or antisense RLMP oligonucleotide was incubated in MEM for 45 minutes at room temperature. Following that incubation, either more MEM or pre-incubated lipofectamine/MEM (7% v/v; incubated 45 minutes at room temperature) was added to achieve an oligonucleotide concentration of 0.2 M. The resulting mixture was incubated for 15 minutes at room temperature. Oligonucleotide mixtures were then mixed with the appropriate medium, that is, MEM/Ascorbate/ $\pm$ Trm, to achieve a final oligonucleotide concentration of 0.1 M.

[0058] Cells were incubated with the appropriate medium ($\pm$ stimulus) in the presence or absence of the appropriate oligonucleotides. Cultures originally incubated with lipofectamine were re-fed after 4 hours of incubation (37°C; 5% CO₂) with media containing neither lipofectamine nor oligonucleotide. All cultures, especially cultures receiving oligonucleotide, were re-fed every 24 hours to maintain oligonucleotide levels.

[0059] LMP-1 antisense oligonucleotide inhibited mineralized nodule formation and osteocalcin secretion in a dose-dependent manner, similar to the effect of BMP-6 oligonucleotide. The LMP-1 antisense block in osteoblast differentiation could not be rescued by addition of exogenous BMP-6, while the BMP-6 antisense oligonucleotide inhibition was reversed with addition of BMP-6. This experiment further confirmed the upstream position of LMP-1 relative to BMP-6 in the osteoblast differentiation pathway. LMP-1 antisense oligonucleotide also inhibited spontaneous osteoblast differentiation in primary rat osteoblast cultures.

EXAMPLE 3: Quantitation of Mineralized Bone Nodule Formation

[0060] Cultures of ROBs prepared according to Examples 1 and 2 were fixed overnight in 70% ethanol and stained with von Kossa silver stain. A semi-automated computerized video image analysis system was used to quantitate nodule count and nodule area in each well. Boden et al., *Endocrinology*, 137(8):3401-07 (1996). These values were then divided to calculate the area per nodule values. This automated process was validated against a manual counting technique and demonstrated a correlation coefficient of 0.92 ($p < 0.000001$). All data are expressed as the mean $\pm$ standard error

of the mean (S.E.M.) calculated from 5 or 6 wells at each condition. Each experiment was confirmed at least twice using cells from different calvarial preparations.

EXAMPLE 4: Quantitation of Osteocalcin Secretion

[0061] Osteocalcin levels in the culture media were measured using a competitive radioimmunoassay with a mono-specific polyclonal antibody (Pab) raised in our laboratory against the C-terminal nonapeptide of rat osteocalcin as described in Nanes et al., Endocrinology, 127:588 (1990). Briefly, 1 g of nonapeptide was iodinated with 1 mCi ^{125}I -Na by the lactoperoxidase method. Tubes containing 200 l of assay buffer (0.02 M sodium phosphate, 1 mM EDTA, 0.001 % thimerosal, 0.025% BSA) received media taken from cell cultures or osteocalcin standards (0 - 12,000 fmole) at 100 l/tube in assay buffer. The Pab (1:40,000; 100 l) was then added, followed by the iodinated peptide (12,000 cpm; 100 l). Samples tested for non-specific binding were prepared similarly but contained no antibody.

[0062] Bound and free PABs were separated by the addition of 700 l goat anti-rabbit IgG, followed by incubation for 18 hours at 4°C. After samples were centrifuged at 1200 rpm for 45 minutes, the supernatants were decanted and the precipitates counted in a gamma counter. Osteocalcin values were reported in fmole/100 l, which was then converted to pmole/ml medium (3-day production) by dividing those values by 100. Values were expressed as the mean $\pm$ S.E.M. of triplicate determinations for 5-6 wells for each condition. Each experiment was confirmed at least two times using cells from different calvarial preparations.

EXAMPLE 5: Effect of Trm and RLMP on Mineralization *In Vitro*

[0063] There was little apparent effect of either the sense or antisense oligonucleotides on the overall production of bone nodules in the non-stimulated cell culture system. When ROBAs were stimulated with Trm, however, the antisense oligonucleotide to RLMP inhibited mineralization of nodules by > 95%. The addition of exogenous BMP-6 to the oligonucleotide-treated cultures did not rescue the mineralization of RLMP-antisense-treated nodules.

[0064] Osteocalcin has long been synonymous with bone mineralization, and osteocalcin levels have been correlated with nodule production and mineralization. The RLMP-antisense oligonucleotide significantly decreases osteocalcin production, but the nodule count in antisense-treated cultures does not change significantly. In this case, the addition of exogenous BMP-6 only rescued the production of osteocalcin in RLMP-antisense-treated cultures by 10-15%. This suggests that the action of RLMP is downstream of, and more specific than, BMP-6.

EXAMPLE 6: Harvest and Purification of RNA

[0065] Cellular RNA from duplicate wells of ROBAs (prepared according to Examples 1 and 2 in 6-well culture dishes) was harvested using 4M guanidine isothiocyanate (GIT) solution to yield statistical triplicates. Briefly, culture supernatant was aspirated from the wells, which were then overlaid with 0.6 ml of GIT solution per duplicate well harvest. After adding the GIT solution, the plates were swirled for 5-10 seconds (being as consistent as possible). Samples were saved at -70°C for up to 7 days before further processing.

[0066] RNA was purified by a slight modification of standard methods according to Sambrook et al., Molecular Cloning: a Laboratory Manual, 2nd Ed., chapter 7.19, Cold Spring Harbor Press (1989). Briefly, thawed samples received 60 l 2.0 M sodium acetate (pH 4.0), 550 l phenol (water saturated) and 150 l chloroform:isoamyl alcohol (49:1). After vortexing, the samples were centrifuged (10000 x g; 20 minutes; 4°C), the aqueous phase transferred to a fresh tube, 600 l isopropanol was added and the RNA precipitated overnight at -20°C.

[0067] Following the overnight incubation, the samples were centrifuged (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets were resuspended in 400 l DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at -20°C after addition of 40 l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. To recover the cellular RNA, the samples were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 l of DEPC-treated water. RNA concentrations were calculated from optical densities that were determined with a spectrophotometer.

EXAMPLE 7: Reverse Transcription-Polymerase Chain Reaction

[0068] Heated total RNA (5 g in 10.5 l total volume DEPC-H₂O at 65°C for 5 minutes) was added to tubes containing 4 l 5X MMLV-RT buffer, 2 l dNTPs, 2 l dT17 primer (10 pmol/ml), 0.5 l RNasin (40U/ml) and 1 l MMLV-RT (200 units/l). The samples were incubated at 37°C for 1 hour, then at 95°C for 5 minutes to inactivate the MMLV-RT. The samples were diluted by addition of 80 l of water.

[0069] Reverse-transcribed samples (5 l) were subjected to polymerase-chain reaction using standard methodologies (50 l total volume). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer, 25

mM MgCl₂, dNTPs, forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAP, a housekeeping gene) and/or BMP-6), ³²P-dCTP, and Taq polymerase. Unless otherwise noted, primers were standardized to run consistently at 22 cycles (94°C, 30"; 58°C, 30"; 72°C, 20").

EXAMPLE 8: Quantitation of RT-PCR Products by Polyacrylamide Gel Electrophoresis (PAGE) and PhosphorImager Analysis

[0070] RT-PCR products received 5 l/tube loading dye, were mixed, heated at 65°C for 10 min and centrifuged. Ten l of each reaction was subjected to PAGE (12% polyacrylamide:bis; 15 V/well; constant current) under standard conditions. Gels were then incubated in gel preserving buffer (10% v/v glycerol, 7% v/v acetic acid, 40% v/v methanol, 43% deionized water) for 30 minutes, dried (80°C) *in vacuo* for 1-2 hours and developed with an electronically-enhanced phosphorescence imaging system for 6-24 hours. Visualized bands were analyzed. Counts per band were plotted graphically.

EXAMPLE 9: Differential Display PCR

[0071] RNA was extracted from cells stimulated with glucocorticoid (Trm, 1 nM). Heated, DNase-treated total RNA (5 g in 10.5 l total volume in DEPC-H₂O at 65°C for 5 minutes) was reverse transcribed as described in Example 7, but H-T₁₁M (SEQ ID. NO: 4) was used as the MMLV-RT primer. The resulting cDNAs were PCR-amplified as described above, but with various commercial primer sets (for example, H-T₁₁G (SEQ ID NO: 4) and H-AP-10 (SEQ ID. NO: 5); GenHunter Corp, Nashville, TN). Radiolabelled PCR products were fractionated by gel electrophoresis on a DNA sequencing gel. After electrophoresis, the resulting gels were dried *in vacuo* and autoradiographs were exposed overnight. Bands representing differentially-expressed cDNAs were excised from the gel and reamplified by PCR using the method of Conner et al., Proc. Natl. Acad. Sci. USA, 88:278 (1983). The products of PCR reamplification were cloned into the vector PCR-II (TA cloning kit; InVitrogen, Carlsbad, CA).

EXAMPLE 10: Screening of a UMR 106 Rat Osteosarcoma Cell cDNA Library

[0072] A UMR 106 library (2.5 x 10¹⁰ pfu/ml) was plated at 5 x 10⁴ pfu/ml onto agar plates (LB bottom agar) and the plates were incubated overnight at 37°C. Filter membranes were overlaid onto plates for two minutes. Once removed, the filters were denatured, rinsed, dried and UV cross-linked. The filters were then incubated in pre-hybridization buffer (2X PIPES [pH 6.5], 5% formamide, 1 % SDS and 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A 260 base-pair radiolabelled probe (SEQ ID NO: 3; ³²P labelled by random priming) was added to the entire hybridization mix/filters, followed by hybridization for 18 hours at 42°C. The membranes were washed once at room temperature (10 min, 1 x SSC, 0.1 % SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1 % SDS).

[0073] After they were washed, the membranes were analyzed by autoradiography as described above. Positive clones were plaque purified. The procedure was repeated with a second filter for four minutes to minimize spurious positives. Plaque-purified clones were rescued as lambda SK(-) phagemids. Cloned cDNAs were sequenced as described below.

EXAMPLE 11: Sequencing of Clones

[0074] Cloned cDNA inserts were sequenced by standard methods. Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience (1988). Briefly, appropriate concentrations of termination mixture, template and reaction mixture were subjected to an appropriate cycling protocol (95°C, 30s; 68°C, 30s; 72°C, 60s; x 25). Stop mixture was added to terminate the sequencing reactions. After heating at 92°C for 3 minutes, the samples were loaded onto a denaturing 6% polyacrylamide sequencing gel (29:1 acrylamide:bisacrylamide). Samples were electrophoresed for about 4 hours at 60 volts, constant current. After electrophoresis, the gels were dried *in vacuo* and autoradiographed.

[0075] The autoradiographs were analyzed manually. The resulting sequences were screened against the databases maintained by the National Center for Biotechnology Information (NIH, Bethesda, MD; <http://www.ncbi.nlm.nih.gov/>) using the BLASTn program set with default parameters. Based on the sequence data, new sequencing primers were prepared and the process was repeated until the entire gene had been sequenced. All sequences were confirmed a minimum of three times in both orientations.

[0076] Nucleotide and amino acid sequences were also analyzed using the PCGENE software package (version 16.0). Per cent homology values for nucleotide sequences were calculated by the program NALIGN, using the following parameters: weight of non-matching nucleotides, 10; weight of non-matching gaps, 10; maximum number of nucleotides considered, 50; and minimum number of nucleotides considered, 50.

[0077] For amino acid sequences, per cent homology values were calculated using PALIGN. A value of 10 was selected

for both the open gap cost and the unit gap cost.

EXAMPLE 12: Cloning of RLMP cDNA

[0078] The differential display PCR amplification products described in Example 9 contained a major band of approximately 260 base pairs. This sequence was used to screen a rat osteosarcoma (UMR 106) cDNA library. Positive clones were subjected to nested primer analysis to obtain the primer sequences necessary for amplifying the full length cDNA. (SEQ. ID NOs: 11, 12, 29, 30 and 31) One of those positive clones selected for further study was designated clone 10-4.

[0079] Sequence analysis of the full-length cDNA in clone 10-4, determined by nested primer analysis, showed that clone 10-4 contained the original 260 base-pair fragment identified by differential display PCR. Clone 10-4 (1696 base pairs; SEQ ID NO: 2) contains an open reading frame of 1371 base pairs encoding a protein having 457 amino acids (SEQ ID NO: 1). The termination codon, TGA, occurs at nucleotides 1444-1446. The polyadenylation signal at nucleotides 1675-1680, and adjacent poly(A)* tail, was present in the 3' noncoding region. There were two potential N-glycosylation sites, Asn-Lys-Thr and Asn-Arg-Thr, at amino acid positions 113-116 and 257-259 in SEQ ID NO: 1, respectively. Two potential cAMP- and cGMP-dependent protein kinase phosphorylation sites, Ser and Thr, were found at amino acid positions 191 and 349, respectively. There were five potential protein kinase C phosphorylation sites, Ser or Thr, at amino acid positions 3, 115, 166, 219, 442. One potential ATP/GTP binding site motif A (P-loop), Gly-Gly-Ser-Asn-Asn-Gly-Lys-Thr, was determined at amino acid positions 272-279.

[0080] In addition, two highly conserved putative LIM domains were found at amino acid positions 341-391 and 400-451. The putative LIM domains in this newly identified rat cDNA clone showed considerable homology with the LIM domains of other known LIM proteins. However, the overall homology with other rat LIM proteins was less than 25%. RLMP (also designated 10-4) has 78.5% amino acid homology to the human enigma protein (see U.S. Patent No. 5,504,192), but only 24.5% and 22.7% amino acid homology to its closest rat homologs, CLP-36 and RIT-18, respectively.

EXAMPLE 13: Northern Blot Analysis of RLMP Expression

[0081] Thirty g of total RNA from ROB's, prepared according to Examples 1 and 2, was size fractionated by formaldehyde gel electrophoresis in 1 % agarose flatbed gels and osmotically transblotted to nylon membranes. The blot was probed with a 600 base pair *Eco*R1 fragment of full-length 10-4 cDNA labeled with ³²P-dCTP by random priming.

[0082] Northern blot analysis showed a 1.7 kb mRNA species that hybridized with the RLMP probe. RLMP mRNA was up-regulated approximately 3.7-fold in ROB's after 24 hours exposure to BMP-6. No up-regulation of RLMP expression was seen in BMP-2 or BMP-4-stimulated ROB's at 24 hours.

EXAMPLE 14: Statistical Methods

[0083] For each reported nodule/osteocalcin result, data from 5-6 wells from a representative experiment were used to calculate the mean $\pm$ S.E.M. Graphs may be shown with data normalized to the maximum value for each parameter to allow simultaneous graphing of nodule counts, mineralized areas and osteocalcin.

[0084] For each reported RT-PCR, RNase protection assay or Western blot analysis, data from triplicate samples of representative experiments, were used to determine the mean $\pm$ S.E.M. Graphs may be shown normalized to either day 0 or negative controls and expressed as fold-increase above control values.

[0085] Statistical significance was evaluated using a one-way analysis of variance with post-hoc multiple comparison corrections of Bonferroni as appropriate. D. V. Huntsberger, "The Analysis of Variance," in Elements of Statistical Variance, P. Billingsley (ed.), pp. 298-330, Allyn & Bacon Inc., Boston, MA (1977) and Sigmapstat, Jandel Scientific, Corte Madera, CA. Alpha levels for significance were defined as $p < 0.05$.

EXAMPLE 15: Detection of Rat LIM Mineralization Protein by Western Blot Analysis

[0086] Polyclonal antibodies were prepared according to the methods of England et al., Biochim.Biophys. Acta, 623: 171 (1980) and Timmer et al., J. Biol. Chem., 268:24863 (1993).

[0087] HeLa cells were transfected with pCMV2/RLMP. Protein was harvested from the transfected cells according to the method of Hair et al., Leukemia Research, 20:1 (1996). Western Blot Analysis of native RLMP was performed as described by Towbin et al., Proc. Natl. Acad. Sci. USA, 76:4350 (1979).

EXAMPLE 16: Synthesis of the Rat LMP-Unique (RLMPU) derived Human PCR product

[0088] Based on the sequence of the rat LMP-1 cDNA, forward and reverse PCR primers (SEQ ID NOs: 15 and 16) were synthesized and a unique 223 base-pair sequence was PCR amplified from the rat LMP-1 cDNA. A similar PCR

product was isolated from human MG63 osteosarcoma cell cDNA with the same PCR primers.

[0089] RNA was harvested from MG63 osteosarcoma cells grown in T-75 flasks. Culture supernatant was removed by aspiration and the flasks were overlaid with 3.0 ml of GIT solution per duplicate, swirled for 5-10 seconds, and the resulting solution was transferred to 1.5 ml eppendorf tubes (5 tubes with 0.6 ml/tube). RNA was purified by a slight modification of standard methods, for example, see Sambrook et al., *Molecular Cloning: A Laboratory Manual*, chapter 7, page 19, Cold Spring Harbor Laboratory Press (1989) and Boden et al., *Endocrinology*, 138:2820-28 (1997). Briefly, the 0.6 ml samples received 60 μ l 12.0 M sodium acetate (pH 4.0), 550 μ l water saturated phenol and 150 μ l chloroform: isoamyl alcohol (49:1). After addition of those reagents, the samples were vortexed, centrifuged (10000 x g; 20 min; 4°C) and the aqueous phase transferred to a fresh tube. Isopropanol (600 μ l) was added and the RNA was precipitated overnight at -20°C. The samples were centrifuged (10000 x g; 20 minutes) and the supernatant was aspirated gently. The pellets were resuspended in 400 μ l of DEPC-treated water, extracted once with phenol:chloroform (1:1), extracted with chloroform:isoamyl alcohol (24:1) and precipitated overnight at -20°C in 40 μ l sodium acetate (3.0 M; pH 5.2) and 1.0 ml absolute ethanol. After precipitation, the samples were centrifuged (10000 x g; 20 min), washed once with 70% ethanol, air dried for 5-10 minutes and resuspended in 20 μ l of DEPC-treated water. RNA concentrations were derived from optical densities.

[0090] Total RNA (5 g in 10.5 L total volume in DEPC-H₂O) was heated at 65°C for 5 minutes, and then added to tubes containing 4 μ l 5X MMLV-RT buffer, 2 μ l dNTPs, 2 μ l dT17 primer (10 pmol/ml), 0.5 μ l RNasin (40 U/ml) and 1 μ l MMLV-RT (200 units/ μ l). The reactions were incubated at 37°C for 1 hour. Afterward, the MMLV-RT was inactivated by heating at 95°C for 5 minutes. The samples were diluted by addition of 80 L water.

[0091] Transcribed samples (5 μ l) were subjected to polymerase-chain reaction using standard methodologies (50 μ l total volume). Boden et al., *Endocrinology*, 138:2820-28 (1997); Ausubel et al., "Quantitation of rare DNAs by the polymerase chain reaction", in *Current Protocols in Molecular Biology*, chapter 15.31-1, Wiley & Sons, Trenton, NJ (1990). Briefly, samples were added to tubes containing water and appropriate amounts of PCR buffer (25 mM MgCl₂, dNTPs, forward and reverse primers (for RLMPU; SEQ ID NOs: 15 and 16), ³²P-dCTP, and DNA polymerase. Primers were designed to run consistently at 22 cycles for radioactive band detection and 33 cycles for amplification of PCR product for use as a screening probe (94°C, 30 sec, 58°C, 30 sec; 72°C, 20 sec).

[0092] Sequencing of the agarose gel-purified MG63 osteosarcoma-derived PCR product gave a sequence more than 95% homologous to the RLMPU PCR product. That sequence is designated HLMP unique region (HLMPU; SEQ ID NO: 6).

EXAMPLE 17: Screening of reverse-transcriptase-derived MG63 cDNA

[0093] Screening was performed with PCR using specific primers (SEQ ID NOs: 16 and 17) as described in Example 7. A 717 base-pair MG63 PCR product was agarose gel purified and sequenced with the given primers (SEQ. ID NOs: 12, 15, 16, 17, 18, 27 and 28). Sequences were confirmed a minimum of two times in both directions. The MG63 sequences were aligned against each other and then against the full-length rat LMP cDNA sequence to obtain a partial human LMP cDNA sequence (SEQ ID NO: 7).

EXAMPLE 18: Screening of a Human Heart cDNA Library

[0094] Based on Northern blot experiments, it was determined that LMP-1 is expressed at different levels by several different tissues, including human heart muscle. A human heart cDNA library was therefore examined. The library was plated at 5 x 10⁴ pfu/ml onto agar plates (LB bottom agar) and plates were grown overnight at 37° C. Filter membranes were overlaid onto the plates for two minutes. Afterward, the filters denatured, rinsed, dried, UV cross-linked and incubated in pre-hybridization buffer (2X PIPES [pH 6.5]; 5% formamide, 1 % SDS, 100 g/ml denatured salmon sperm DNA) for 2 h at 42°C. A radiolabelled, LMP-unique, 223 base-pair probe (³²P, random primer labelling; SEQ ID NO: 6) was added and hybridized for 18 h at 42°C. Following hybridization, the membranes were washed once at room temperature (10 min, 1 x SSC, 0.1% SDS) and three times at 55°C (15 min, 0.1 x SSC, 0.1 % SDS). Double-positive plaque-purified heart library clones, identified by autoradiography, were rescued as lambda phagemids according to the manufacturers' protocols (Stratagene, La Jolla, CA).

[0095] Restriction digests of positive clones yielded cDNA inserts of varying sizes. Inserts greater than 600 base-pairs in length were selected for initial screening by sequencing. Those inserts were sequenced by standard methods as described in Example 11.

[0096] One clone, number 7, was also subjected to automated sequence analysis using primers corresponding to SEQ ID NOs: 11-14, 16 and 27. The sequences obtained by these methods were routinely 97-100% homologous. Clone 7 (Partial Human LMP-1 cDNA from a heart library; SEQ. ID NO: 8) contained sequence that was more than 87% homologous to the rat LMP cDNA sequence in the translated region.

EXAMPLE 19: Determination of Full-Length Human LMP-1 cDNA

[0097] Overlapping regions of the MG63 human osteosarcoma cell cDNA sequence and the human heart cDNA clone 7 sequence were used to align those two sequences and derive a complete human cDNA sequence of 1644 base-pairs. NALIGN, a program in the PCGENE software package, was used to align the two sequences. The overlapping regions of the two sequences constituted approximately 360 base-pairs having complete homology except for a single nucleotide substitution at nucleotide 672 in the MG63 cDNA (SEQ ID NO: 7) with clone 7 having an "A" instead of a "G" at the corresponding nucleotide 516 (SEQ ID NO: 8).

[0098] The two aligned sequences were joined using SEQIN, another subprogram of PCGENE, using the "G" substitution of the MG63 osteosarcoma cDNA clone. The resulting sequence is shown in SEQ ID NO: 9. Alignment of the novel human-derived sequence with the rat LMP-1 cDNA was accomplished with NALIGN. The full-length human LMP-1 cDNA sequence (SEQ. ID NO: 9) is 87.3% homologous to the translated portion of rat LMP-1 cDNA sequence.

EXAMPLE 20: Determination of Amino Acid Sequence of Human LMP-1

[0099] The putative amino acid sequence of human LMP-1 was determined with the PCGENE subprogram TRANSL. The open reading frame in SEQ ID NO: 9 encodes a protein comprising 457 amino acids (SEQ. ID NO: 10). Using the PCGENE subprogram Palign, the human LMP-1 amino acid sequence was found to be 94.1 % homologous to the rat LMP-1 amino acid sequence.

EXAMPLE 21: Determination of the 5 Prime Untranslated Region of the Human LMP cDNA

[0100] MG63 5' cDNA was amplified by nested RT-PCR of MG63 total RNA using a 5' rapid amplification of cDNA ends (5' RACE) protocol. This method included first strand cDNA synthesis using a lock-docking oligo (dT) primer with two degenerate nucleotide positions at the 3' end (Chenchik et al., CLONTECHniques, X:5 (1995); Borson et al., PC Methods Applic., 2:144 (1993)). Second-strand synthesis is performed according to the method of Gubler et al., Gene, 25:263 (1983), with a cocktail of *Escherichia coli* DNA polymerase I, RNase H, and *E. coli* DNA ligase. After creation of blunt ends with T4 DNA polymerase, double-stranded cDNA was ligated to the fragment (5'-CTAATACGACTCACTAT-AGGGCTCGAGCGGCCCGCCGGGCAGGT-3') (SEQ.ID NO: 19). Prior to RACE, the adaptor-ligated cDNA was diluted to a concentration suitable for Marathon RACE reactions (1:50). Adaptor-ligated double-stranded cDNA was then ready to be specifically cloned.

[0101] First-round PCR was performed with the adaptor-specific oligonucleotide, 5'-CCATCCTAATACGACTCAC-TATAGGGC- 3' (AP1) (SEQ.ID NO: 20) as sense primer and a Gene Specific Primer (GSP) from the unique region described in Example 16 (HLMPU). The second round of PCR was performed using a nested primers GSP1-HLMPU (antisense/reverse primer) (SEQ. ID NO: 23) and GSP2-HLMPUF (SEQ. ID NO: 24) (see Example 16; sense/forward primer). PCR was performed using a commercial kit (Advantage cDNA PCR core kit; CloneTech Laboratories Inc., Palo Alto, CA) that utilizes an antibody-mediated, but otherwise standard, hot-start protocol. PCR conditions for MG63 cDNA included an initial hot-start denaturation (94°C, 60 sec) followed by: 94°C, 30 sec; 60°C, 30 sec; 68°C, 4 min; 30 cycles. The first-round PCR product was approximately 750 base-pairs in length whereas the nested PCR product was approximately 230 base-pairs. The first-round PCR product was cloned into linearized pCR 2.1 vector (3.9 Kb). The inserts were sequenced in both directions using M13 Forward and Reverse primers (SEQ. ID NO: 11; SEQ. ID NO: 12)

EXAMPLE 22: Determination of Full-length Human LMP-1 cDNA with 5 Prime UTR

[0102] Overlapping MG63 human osteosarcoma cell cDNA 5'-UTR sequence (SEQ ID NO: 21), MG63 717 base-pair sequence (Example 17; SEQ ID NO: 8) and human heart cDNA clone 7 sequence (Example 18) were aligned to derive a novel human cDNA sequence of 1704 base-pairs (SEQ.ID NO: 22). The alignment was accomplished with NALIGN, (both PCGENE and Omega 1.0; Intelligenetics). Over-lapping sequences constituted nearly the entire 717 base-pair region (Example 17) with 100% homology. Joining of the aligned sequences was accomplished with SEQIN.

EXAMPLE 23: Construction of LIM Protein Expression Vector

[0103] The construction of pHIS-SATG LMP-1s expression vector was carried out with the sequences described in Examples 17 and 18. The 717 base-pair clone (Example 17; SEQ ID NO: 7) was digested with *Clal* and *EcoRV*. A small fragment (~250 base-pairs) was gel purified. Clone 7 (Example 18; SEQ ID NO: 8) was digested with *Clal* and *XbaI* and a 1400 base-pair fragment was gel purified. The isolated 250 base-pair and 1400 base-pair restriction fragments were ligated to form a fragment of ~1650 base-pairs.

[0104] Due to the single nucleotide substitution in Clone 7 (relative to the 717 base-pair PCR sequence and the original

rat sequence) a stop codon at translated base-pair 672 resulted. Because of this stop codon, a truncated (short) protein was encoded, hence the name LMP-1 s. This was the construct used in the expression vector (SEQ ID NO: 32). The full length cDNA sequence with 5' UTR (SEQ ID NO: 33) was created by alignment of SEQ ID NO: 32 with the 5' RACE sequence (SEQ ID NO: 21). The amino acid sequence of LMP-1s (SEQ ID NO: 34) was then deduced as a 223 amino acid protein and confirmed by Western blot (as in Example 15) to run at the predicted molecular weight of - 23.7 kD.

[0105] The pHIS-ATG vector (InVitrogen, Carlsbad, CA) was digested with *EcoRV* and *XbaI*. The vector was recovered and the 1650 base-pair restriction fragment was then ligated into the linearized pHIS-ATG. The ligated product was cloned and amplified. The pHIS-ATG-LMP-1s Expression vector, also designated pHIS-A with insert HLMP-1 s, was purified by standard methods.

EXAMPLE 24: Induction of Bone Nodule Formation and Mineralization *In vitro* with LMP Expression Vector

[0106] Rat Calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) as described in Example 1. A modification of the Superfect Reagent (Qiagen, Valencia, CA) transfection protocol was used to transfect 3 g/well of each vector into secondary rat calvarial osteoblast cultures according to Example 25.

Mineralized nodules were visualized by Von Kossa staining, as described in Example 3. Human LMP-1s gene product overexpression alone induced bone nodule formation (~203 nodules/well) *in vitro*. Levels of nodules were approximately 50% of those induced by the GC positive control (~412 nodules/well). Other positive controls included the pHIS-A-LMP-Rat expression vector (~152 nodules/well) and the pCMV2/LMP-Rat-Fwd Expression vector (~206 nodules/well), whereas the negative controls included the pCMV2/LMP-Rat-Rev. Expression vector (~2 nodules/well) and untreated (NT) plates (~4 nodules/well). These data demonstrate that the human cDNA was at least as osteoinductive as the rat cDNA. The effect was less than that observed with GC stimulation, most likely due to suboptimal doses of Expression vector.

EXAMPLE 25: LMP-Induced Cell Differentiation *In Vitro* and *In Vivo*

[0107] The rat LMP cDNA in clone 10-4 (see Example 12) was excised from the vector by double-digesting the clone with *NotI* and *Apal* overnight at 37°C. Vector pCMV2 MCS (InVitrogen, Carlsbad, CA) was digested with the same restriction enzymes. Both the linear cDNA fragment from clone 10-4 and pCMV2 were gel purified, extracted and ligated with T4 ligase. The ligated DNA was gel purified, extracted and used to transform *E. coli* JM109 cells for amplification. Positive agar colonies were picked, digested with *NotI* and *Apal* and the restriction digests were examined by gel electrophoresis. Stock cultures were prepared of positive clones.

[0108] A reverse vector was prepared in analogous fashion except that the restriction enzymes used were *XbaI* and *HindIII*. Because these restriction enzymes were used, the LMP cDNA fragment from clone 10-4 was inserted into pRc/CMV2 in the reverse (that is, non-translatable) orientation. The recombinant vector produced is designated pCMV2/RLMP.

[0109] An appropriate volume of pCMV10-4 (60 nM final concentration is optimal [3 g]; for this experiment a range of 0-600 nM/well [0-30 g/well] final concentration is preferred) was resuspended in Minimal Eagle Media (MEM) to 450 l final volume and vortexed for 10 seconds. Superfect was added (7.5 l/ml final solution), the solution was vortexed for 10 seconds and then incubated at room temperature for 10 minutes. Following this incubation, MEM supplemented with 10% FBS (1 ml/well; 6 ml/plate) was added and mixed by pipetting.

[0110] The resulting solution was then promptly pipetted (1 ml/well) onto washed ROB cultures. The cultures were incubated for 2 hours at 37°C in a humidified atmosphere containing 5% CO₂. Afterward, the cells were gently washed once with sterile PBS and the appropriate normal incubation medium was added.

[0111] Results demonstrated significant bone nodule formation in all rat cell cultures which were induced with pCMV10-4. For example, pCMV10-4 transfected cells produced 429 nodules/well. Positive control cultures, which were exposed to Trm, produced 460 nodules/well. In contrast, negative controls, which received no treatment, produced 1 nodule/well. Similarly, when cultures were transfected with pCMV10-4 (reverse), no nodules were observed.

[0112] For demonstrating *de novo* bone formation *in vivo*, marrow was aspirated from the hindlimbs of 4-5 week old normal rats (mu/+; heterozygous for recessive athymic condition). The aspirated marrow cells were washed in alpha MEM, centrifuged, and RBCs were lysed by resuspending the pellet in 0.83% NH₄Cl in 10 mM Tris (pH 7.4). The remaining marrow cells were washed 3x with MEM and transfected for 2 hours with 9 g of pCMV-LMP-1s (forward or reverse orientation) per 3 x 10⁶ cells. The transfected cells were then washed 2X with MEM and resuspended at a concentration of 3 x 10⁷ cells/ml.

[0113] The cell suspension (100 l) was applied via sterile pipette to a sterile 2 x 5 mm type I bovine collagen disc (Sulzer Orthopaedics, Wheat Ridge, CO). The discs were surgically implanted subcutaneously on the skull, chest, abdomen or dorsal spine of 4-5 week old athymic rats (rnu/rnu). The animals were scarified at 3-4 weeks, at which time the discs or surgical areas were excised and fixed in 70% ethanol. The fixed specimens were analyzed by radiography

and undecalcified histologic examination was performed on 5 m thick sections stained with Goldner Trichrome. Experiments were also performed using devitalized (guanidine extracted) demineralized bone matrix (Osteotech, Shrewsbury, NJ) in place of collagen discs.

[0114] Radiography revealed a high level of mineralized bone formation that conformed to the form of the original collagen disc containing LMP-1s transfected marrow cells. No mineralized bone formation was observed in the negative control (cells transfected with a reverse-oriented version of the LMP-1 s cDNA that did not code for a translated protein), and absorption of the carrier appeared to be well underway.

[0115] Histology revealed new bone trabeculae lined with osteoblasts in the LMP-1s transfected implants. No bone was seen along with partial resorption of the carrier in the negative controls.

[0116] Radiography of a further experiment in which 18 sets (9 negative control pCMV-LMP-REV & 9 experimental pCMV-LMP-1s) of implants were added to sites alternating between lumbar and thoracic spine in athymic rats demonstrated 0/9 negative control implants exhibiting bone formation (spine fusion) between vertebrae. All nine of the pCMV-LMP-1s treated implants exhibited solid bone fusions between vertebrae.

EXAMPLE 26: The Synthesis of pHIS-5' ATG LMP-1s Expression Vector from the sequences Demonstrated in Examples 2 and 3,

[0117] The 717 base-pair clone (Example 17) was digested with Clal and EcoRV (New England Biologicals, city, MA). A small fragment (~250 base-pairs) was gel purified. Clone No. 7 (Example 18) was digested with Clal and Xbal. A 1400 base-pair fragment was gel purified from that digest. The isolated 250 base-pair and 1400 base-pair cDNA fragments were ligated by standard methods to form a fragment of ~1650 bp. The pHis-A vector (Invitrogen) was digested with EcoRV and Xbal. The linearized vector was recovered and ligated to the chimeric 1650 base-pair cDNA fragment. The ligated product was cloned and amplified by standard methods, and the pHis-A-5' ATG LMP-1 s expression vector, also denominated as the vector pHis-A with insert HLMP-1s, was deposited at the ATCC as previously described.

EXAMPLE 27: The Induction of Bone Nodule Formation and Mineralization *In Vitro* With pHis-5' ATG LMP-1 s Expression Vector

[0118] Rat calvarial cells were isolated and grown in secondary culture according to Example 1. Cultures were either unstimulated or stimulated with glucocorticoid (GC) according to Example 1. The cultures were transfected with 3 g of recombinant pHis-A vector DNA/well as described in Example 25. Mineralized nodules were visualized by Von Kossa staining according to Example 3.

[0119] Human LMP-1s gene product overexpression alone (*i.e.*, without GC stimulation) induced significant bone nodule formation (~203 nodules/well) *in vitro*. This is approximately 50% of the amount of nodules produced by cells exposed to the GC positive control (~412 nodules/well). Similar results were obtained with cultures transfected with pHisA-LMP-Rat Expression vector (~152 nodules/well) and pCMV2/LMP-Rat-Fwd (~206 nodules/well). In contrast, the negative control pCMV2/LMP-Rat-Rev yielded (~2 nodules/well), while approximately 4 nodules/well were seen in the untreated plates. These data demonstrate that the human LMP-1 cDNA was at least as osteoinductive as the rat LMP-1 cDNA in this model system. The effect in this experiment was less than that observed with GC stimulation; but in some the effect was comparable.

EXAMPLE 28: LMP Induces Secretion of a Soluble Osteoinductive Factor

[0120] Overexpression of RLMP-1 or HLMP-1 s in rat calvarial osteoblast cultures as described in Example 24 resulted in significantly greater nodule formation than was observed in the negative control. To study the mechanism of action of LIM mineralization protein conditioned medium was harvested at different time points, concentrated to 10 X, sterile filtered, diluted to its original concentration in medium containing fresh serum, and applied for four days to untransfected cells.

[0121] Conditioned media harvested from cells transfected with RLMP-1 or HLMP-1s at day 4 was approximately as effective in inducing nodule formation as direct overexpression of RLMP-1 in transfected cells. Conditioned media from cells transfected with RLMP-1 or HLMP-1 in the reverse orientation had no apparent effect on nodule formation. Nor did conditioned media harvested from LMP-1 transfected cultures before day 4 induce nodule formation. These data suggest that expression of LMP-1 caused the synthesis and/or secretion of a soluble factor, which did not appear in culture medium in effective amounts until 4 days post transfection.

[0122] Since overexpression of rLMP-1 resulted in the secretion of an osteoinductive factor into the medium, Western blot analysis was used to determine if LMP-1 protein was present in the medium. The presence of rLMP-1 protein was assessed using antibody specific for LMP-1 (QDPDEE) and detected by conventional means. LMP-1 protein was found only in the cell layer of the culture and not detected in the medium.

[0123] Partial purification of the osteoinductive soluble factor was accomplished by standard 25% and 100% ammonium sulfate cuts followed by DE-52 anion exchange batch chromatography (100 mM or 500 mM NaCl). All activity was observed in the high ammonium sulfate, high NaCl fractions. Such localization is consistent with the possibility of a single factor being responsible for conditioning the medium.

EXAMPLE 29: Gene Therapy In Lumbar Spine Fusion Mediated by Low Dose Adenovirus

[0124] This study determined the optimal dose of adenoviral delivery of the LMP-1 cDNA (SEQ ID NO: 2) to promote spine fusion in normal, that is, immune competent, rabbits.

[0125] A replication-deficient human recombinant adenovirus was constructed with the LMP-1 cDNA (SEQ ID NO: 2) driven by a CMV promoter using the Adeno-Quest™ Kit (Quantum Biotechnologies, Inc., Montreal). A commercially available (Quantum Biotechnologies, Inc., Montreal) recombinant adenovirus containing the beta-galactosidase gene was used as a control.

[0126] Initially, an *in vitro* dose response experiment was performed to determine the optimal concentration of adenovirus-delivered LMP-1 ("AdV-LMP-1") to induce bone differentiation in rat calvarial osteoblast cultures using a 60-minute transduction with a multiplicity of infection ("MOI") of 0.025, 0.25, 2.5, or 25 plaque-forming units (pfu) of virus per cell. Positive control cultures were differentiated by a 7-day exposure to 10^9 M glucocorticoid ("GC"). Negative control cultures were left untreated. On day 14, the number of mineralized bone nodules was counted after von Kossa staining of the cultures, and the level of osteocalcin secreted into the medium (pmol/mL) was measured by radioimmunoassay (mean $\pm$ SEM).

[0127] The results of this experiment are shown in Table I. Essentially no spontaneous nodules formed in the untreated negative control cultures. The data show that a MOI equal to 0.25 pfu/cell is most effective for osteoinducing bone nodules, achieving a level comparable to the positive control (GC). Lower and higher doses of adenovirus were less effective.

TABLE I

Outcome	AdV-LMP-1 Dose (MOI)					
	Neg. Ctrl.	GC	0.025	0.25	2.5	25
Bone Nodules	0.5 $\pm$ 0.2	188 $\pm$ 35	79.8 $\pm$ 13	145.1 $\pm$ 1	26.4 $\pm$ 15	87.6 $\pm$ 2
Osteocalcin	1.0 $\pm$ 0.1	57.8 $\pm$ 9	28.6 $\pm$ 11	22.8 $\pm$ 1	18.3 $\pm$ 3	26.0 $\pm$ 2

[0128] *In vivo* experiments were then performed to determine if the optimal *in vitro* dose was capable of promoting intertransverse process spine fusions in skeletally mature New Zealand white rabbits. Nine rabbits were anesthetized and 3 cc of bone marrow was aspirated from the distal femur through the intercondylar notch using an 18 gauge needle. The buffy coat was then isolated, a 10-minute transduction with AdV-LMP-1 was performed, and the cells were returned to the operating room for implantation. Single level posterolateral lumbar spine arthrodesis was performed with decor-tication of transverse processes and insertion of carrier (either rabbit devitalized bone matrix or a collagen sponge) containing 8-15 million autologous nucleated buffy coat cells transduced with either AdV-LMP-1 (MOI = 0.4) or AdV-BGal (MOI = 0.4). Rabbits were euthanized after 5 weeks and spine fusions were assessed by manual palpation, plain x-rays, CT scans, and undecalcified histology.

[0129] The spine fusion sites that received AdV-LMP-1 induced solid, continuous spine fusion masses in all nine rabbits. In contrast, the sites receiving AdV-BGal, or a lower dose of AdV-LMP-1 (MOI = 0.04) made little or no bone and resulted in spine fusion at a rate comparable to the carrier alone (< 40%). These results were consistent as evaluated by manual palpation, CT scan, and histology. Plain radiographs, however, sometimes overestimated the amount of bone that was present, especially in the control sites. LMP-1 cDNA delivery and bone induction was successful with both of the carrier materials tested. There was no evidence of systemic or local immune response to the adenovirus vector.

[0130] These data demonstrate consistent bone induction in a previously validated rabbit spine fusion model which is quite challenging. Furthermore, the protocol of using autogenous bone marrow cells with intraoperative *ex vivo* gene transduction (10 minutes) is a more clinically feasible procedure than other methods that call for overnight transduction or cell expansion for weeks in culture. In addition, the most effective dose of recombinant adenovirus (MOI=0.25) was substantially lower than doses reported in other gene therapy applications (MOI=40-500). We believe this is due to the fact that LMP-1 is an intracellular signaling molecule and may have powerful signal amplification cascades. Moreover, the observation that the same concentration of AdV-LMP-1 that induced bone in cell culture was effective *in vivo* was also surprising given the usual required increase in dose of other growth factors when translating from cell culture to animal experiments. Taken together, these observations indicate that local gene therapy using adenovirus to deliver the

LMP-1 cDNA is possible and the low dose required will likely minimize the negative effects of immune response to the adenovirus vector.

EXAMPLE 30: Use of Peripheral Venous Blood Nucleated Cells (Buffy Coat) for Gene Therapy With LMP-1 cDNA To Make Bone

[0131] In four rabbits we performed spine fusion surgery as above (Example 29) except the transduced cells were the buffy coat from venous blood rather than bone marrow. These cells were transfected with Adeno-LMP or pHIS-LMP plasmid and had equivalent successful results as when bone marrow cells were used. This discovery of using ordinary venous blood cells for gene delivery makes gene therapy more feasible clinically since it avoids painful marrow harvest under general anesthesia and yields two times more cells per mL of starting material.

EXAMPLE 31: Isolation of Human LMP-1 Splice Variants

[0132] Intron/Exon mRNA transcript splice variants are a relatively common regulatory mechanism in signal transduction and cellular/tissue development. Splice variants of various genes have been shown to alter protein-protein, protein-DNA, protein-RNA, and protein-substrate interactions. Splice variants may also control tissue specificity for gene expression allowing different forms (and therefore functions) to be expressed in various tissues. Splice variants are a common regulatory phenomenon in cells. It is possible that the LMP splice variants may result in effects in other tissues such as nerve regeneration, muscle regeneration, or development of other tissues.

[0133] To screen a human heart cDNA library for splice variants of the HLMP-1 sequence, a pair of PCR primer corresponding to sections of SEQ ID NO: 22 was prepared. The forward PCR primer, which was synthesized using standard techniques, corresponds to nucleotides 35-54 of SEQ ID NO: 22. It has the following sequence:
5' GAGCCGGCATCATGGATTCC 3' (SEQ ID NO: 35)

[0134] The reverse PCR primer, which is the reverse complement of nucleotides 820-839 in SEQ ID NO: 22, has the following sequence:

5' GCTGCCTGCACAATGGAGGT 3' (SEQ ID NO: 36)

[0135] The forward and reverse PCR primers were used to screen human heart cDNA (ClonTech, Cat No. 7404-1) for sequences similar to HLMP-1 by standard techniques, using a cycling protocol of 94°C for 30 seconds, 64°C for 30 seconds, and 72°C for 1 minute, repeated 30 times and followed by a 10 minute incubation at 72°C. The amplification cDNA sequences were gel-purified and submitted to the Emory DNA Sequence Core Facility for sequencing. The clones were sequenced using standard techniques and the sequences were examined with PCGENE (Intelligenetics; Programs SEQUIN and NALIGN) to determine homology to SEQ ID NO: 22. Two homologous nucleotide sequences with putative alternative splice sites compared to SEQ ID NO: 22 were then translated to their respective protein products with Intelligenetic's program TRANSL.

[0136] One of these two novel human cDNA sequences (SEQ ID NO: 37) comprises 1456 bp:

10 20 30 40 50 60

EP 1 808 182 A1

CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
70 80 90 100 110 120
5 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGACTTCAAT
130 140 150 160 170 180
10 GTGCCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
190 200 210 220 230 240
15 GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
250 260 270 280 290 300
GCTCAGAACA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG
310 320 * 330 340 * 350 360
20 CCGGTTTCTG GCAAACCGCA GAAG~~GTGCAG~~ ~~ACCCCTGACA~~ AACAGCCGCT CCGACCGCTG
370 380 390 400 410 420
25 GTCCCAGATG CCAGCAAGCA GCGGCTGATG GAGAACACAG AGGACTGGCG GCCGCGGCCG
430 440 450 460 470 480
30 GGGACAGGCC AGTCGCGTTC CTTCCGCATC CTTGCCCACC TCACAGGCAC CGAGTTCATG
490 500 510 520 530 540
CAAGACCCGG ATGAGGAGCA CCTGAAGAAA TCAAGCCAGG TGCCCAGGAC AGAAGCCCCA
550 560 570 580 590 600
35 GCCCCAGCCT CATCTACACC CCAGGAGCCC TGGCCTGGCC CTACCGCCCC CAGCCCTACC
610 620 630 640 650 660
40 AGCCGCCCCG CCTGGGCTGT GGACCCTGCG TTTGCCGAGC GCTATGCCCC GGACAAAACG
670 680 690 700 710 720
AGCACAGTGC TGACCCGGCA CAGCCAGCCG GCCACGCCCA CGCCGCTGCA GAGCCGCACC
730 740 750 760 770 780
45 TCCATTGTGC AGGCAGCTGC CGGAGGGGTG CCAGGAGGGG GCAGCAACAA CGGCAAGACT
790 800 810 820 830 840
50 CCCGTGTGTC ACCAGTGCCA CAAGGTCATC CGGGGCCGCT ACCTGGTGGC GTTGGGCCAC
850 860 870 880 890 900
55

EP 1 808 182 A1

GCGTACCACC CGGAGGAGTT TGTGTGTAGC CAGTGTGGGA AGGTCCTGGA AGAGGGTGGC
 910 920 930 940 950 960
 5 TTCTTTGAGG AGAAGGGCGC CATCTTCTGC CCACCATGCT ATGACGTGCG CTATGCACCC
 970 980 990 1000 1010 1020
 10 AGCTGTGCCA AGTGCAAGAA GAAGATTACA GGCAGATCA TGCACGCCCT GAAGATGACC
 1030 1040 1050 1060 1070 1080
 TGGCACGTGC ACTGCTTTAC CTGTGCTGCC TGCAAGACGC CCATCCGGAA CAGGGCCTTC
 15 1090 1100 1110 1120 1130 1140
 TACATGGAGG AGGGCGTGCC CTATTGCGAG CGAGACTATG AGAAGATGTT TGGCACGAAA
 1150 1160 1170 1180 1190 1200
 20 TGCCATGGCT GTGACTTCAA GATCGACGCT GGGGACCGCT TCCTGGAGGC CCTGGGCTTC
 1210 1220 1230 1240 1250 1260
 25 AGCTGGCATG ACACCTGCTT CGTCTGTGCG ATATGTCAGA TCAACCTGGA AGGAAAGACC
 1270 1280 1290 1300 1310 1320
 TTCTACTCCA AGAAGGACAG GCCTCTCTGC AAGAGCCATG CCTTCTCTCA TGTGTGAGCC
 30 1330 1340 1350 1360 1370 1380
 CCTTCTGCCC ACAGCTGCCG CGGTGGCCCC TAGCCTGAGG GGCCTGGAGT CGTGGCCCTG
 1390 1400 1410 1420 1430 1440
 35 CATTTCTGGG TAGGGCTGGC AATGGTTGCC TTAACCCTGG CTCCTGGCCC GAGCCTGGGC
 1450
 40 TCCCGGGCCC TGCCCA

[0137] Reading frame shifts caused by the deletion of a 119 bp fragment (between *) and the addition of a 17 bp fragment (underlined) results in a truncated gene product having the following derived amino acid sequence (SEQ ID NO: 38):

10 20 30 40 50 60

EP 1 808 182 A1

MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
 70 80 90 100 110 120
 5 LTHIEAQNKI RACGERLSLG LSRAQPVQNK PQKVQTPDKQ PLRPLVPDAS KQRLMENTED
 130 140 150 160 170 180
 10 WRPRPGTGQS RSFRILAHLT GTEFMQDPDE EHLKKSSQVP RTEAPAPASS TPQEPWPGPT
 190 200 210 220 230 240
 15 APSPTSRPPW AVDPFAFAERY APDKTSTVLT RHSQPATPTP LQSRTSIVQA AAGGVPPGGGS
 250 260 270 280 290 300
 NNGKTPVCHQ CHQVIRARYL VALGHAYHPE EFVCSQCGKV LEEGGFFEEK GAIFCPPCYD
 310 320 330 340 350 360
 20 VRYAPSCAKC KKKITGEIMH ALKMTWHVLC FTCAACKTPI RNRAFYMEEG VPYCERDYEK
 370 380 390 400 410 420
 25 MFGTKCQWCD FKIDAGDRFL EALGFSWHD TCFVCAICQIN LEGKTFYSKK DRPLCKSHAF
 SHV

- [0138] This 423 amino acid protein demonstrates 100% homology to the protein shown in Sequence ID No. 10, except for the sequence in the highlighted area (amino acids 94-99), which are due to the nucleotide changes depicted above.
 [0139] The second novel human heart cDNA sequence (SEQ ID NO: 39) comprises 1575 bp:

10 20 30 40 50 60
 35 CGACGCAGAG CAGCGCCCTG GCCGGGCCAA GCAGGAGCCG GCATCATGGA TTCCTTCAAG
 70 80 90 100 110 120
 40 GTAGTGCTGG AGGGGCCAGC ACCTTGGGGC TTCCGGCTGC AAGGGGGCAA GGA CTTC AAT
 130 140 150 160 170 180
 45 GTGCCCCCTCT CCATTTCCCG GCTCACTCCT GGGGGCAAAG CGGCGCAGGC CGGAGTGGCC
 190 200 210 220 230 240

EP 1 808 182 A1

GTGGGTGACT GGGTGCTGAG CATCGATGGC GAGAATGCGG GTAGCCTCAC ACACATCGAA
 250 260 270 280 290 300
 5 GCTCAGAACAA AGATCCGGGC CTGCGGGGAG CGCCTCAGCC TGGGCCTCAG CAGGGCCCAG
 310 320 330 340 350 360
 10 CCGGTTTCAGA GCAAACCGCA GAAGGCCTCC GCCCCCGCCG CGGACCCTCC GCGGTACACC
 370 380 390 400 410 420
 15 TTTGCACCCA GCGTCTCCCT CAACAAGACG GCCC GGCCCT TTGGGGCGCC CCCGCCCGCT
 430 440 450 460 470 480
 GACAGCGCCC CGCAACAGAA TGGGTGCAGA CCCCTGACAA ACAGCCGCTC CGACCGCTGG
 490 500 510 520 530 540
 20 TCCCAGATGC CAGCAAGCAG CGGCTGATGG AGAACACAGA GGA CTGGCGG CCGCGGCCGG
 550 560 570 580 590 600
 25 GGACAGGCCA GTCGCGTTCC TTCCGCATCC TTGCCCACCT CACAGGCACC GAGTTCATGC
 610 620 630 640 650 660
 AAGACCCGGA TGAGGAGCAC CTGAAGAAAT CAAGCCAGGT GCCCAGGACA GAAGCCCCAG
 670 680 690 700 710 720
 30 CCCCAGCCTC ATCTACACCC CAGGAGCCCT GGCCTGGCCC TACCGCCCCC AGCCCTACCA
 730 740 750 760 770 780
 35 GCCGCCCCGCC CTGGGCTGTG GACCCTGCGT TTGCCGAGCG CTATGCCCCG GACAAAACGA
 790 800 810 820 830 840
 40 GCACAGTGCT GACCCGGCAC AGCCAGCCGG CCACGCCCAC GCCGCTGCAG AGCCGCACCT
 850 860 870 880 890 900
 CCATTGTGCA GGCAGCTGCC GGAGGGGTGC CAGGAGGGGG CAGCAACAAC GGCAAGACTC
 910 920 930 940 950 960
 45 CCGTGTGTCA CCA GTGCCAC AAGGTCATCC GGGGCCGCTA CCTGGTGGCG TTGGGCCACG
 970 980 990 1000 1010 1020
 50 CGTACCACCC GGAGGAGTTT GTGTGTAGCC AGTGTGGGAA GGTCTGGAA GAGGGTGGCT
 1030 1040 1050 1060 1070 1080
 55

EP 1 808 182 A1

TCTTTGAGGA GAAGGGCGCC ATCTTCTGCC CACCATGCTA TGACGTGCGC TATGCACCCA
 1090 1100 1110 1120 1130 1140
 GCTGTGCCAA GTGCAAGAAG AAGATTACAG GCGAGATCAT GCACGCCCTG AAGATGACCT
 1150 1160 1170 1180 1190 1200
 GGCACGTGCA CTGCTTTACC TGTGCTGCCT GCAAGACGCC CATCCGGAAC AGGGCCTTCT
 1210 1220 1230 1240 1250 1260
 ACATGGAGGA GGGCGTGCCC TATTGCGAGC GAGACTATGA GAAGATGTTT GGCACGAAAT
 1270 1280 1290 1300 1310 1320
 GCCATGGCTG TGAATTCAAG ATCGACGCTG GGGACCGCTT CCTGGAGGCC CTGGGCTTCA
 1330 1340 1350 1360 1370 1380
 GCTGGCATGA CACCTGCTTC GTCTGTGCGA TATGTCAGAT CAACCTGGAA GGAAAGACCT
 1390 1400 1410 1420 1430 1440
 TCTACTCCAA GAAGGACAGG CCTCTCTGCA AGAGCCATGC CTTCTCTCAT GTGTGAGCCC
 1450 1460 1470 1480 1490 1500
 CTTCTGCCCCA CAGCTGCCGC GGTGGCCCCCT AGCCTGAGGG GCCTGGAGTC GTGGCCCTGC
 1510 1520 1530 1540 1550 1560
 ATTTCTGGGT AGGGCTGGCA ATGGTTGCCT TAACCCTGGC TCCTGGCCCG AGCCTGGGCT
 1570
 CCCGGGCCCT GCCCA

[0140] Reading frame shifts caused by the addition of a 17 bp fragment (bolded, italicized and underlined) results in an early translation stop codon at position 565-567 (underlined).

[0141] The derived amino acid sequence (SEQ ID NO: 40) consists of 153 amino acids:

10 20 30 40 50 60
 MDSFKVVLEG PAPWGFRLQG GKDFNVPLSI SRLTPGGKAA QAGVAVGDWV LSIDGENAGS
 70 80 90 100 110 120
 LTHIEAQNKI RACGERLSLG LSRAQPVQSK POKASAPAAD PPRYTFAPSV SLNKTARPFQ
 130 140 150
APPPADSAPO ONGCRPLTNS RSDRWSOMPA SSG

[0142] This protein demonstrates 100% homology to SEQ ID NO: 10 until amino acid 94, where the addition of the 17 bp fragment depicted in the nucleotide sequence results in a frame shift. Over amino acids 94-153, the protein is not homologous to SEQ ID NO: 10. Amino acids 154-457 in SEQ ID NO: 10 are not present due to the early stop codon depicted in nucleotide sequence.

EXAMPLE 32: Genomic HLMP-1 Nucleotide Sequence

[0143] Applicants have identified the genomic DNA sequence encoding HLMP-1, including putative regulatory elements associated with HLMP-1 expression. The entire genomic sequence is shown in SEQ ID. NO: 41. This sequence was derived from AC023788 (clone RP11-564G9), Genome Sequencing Center, Washington University School of Medicine, St. Louis, MO.

[0144] The putative promoter region for HLMP-1 spans nucleotides 2,660-8,733 in SEQ ID NO: 41. This region comprises, among other things, at least ten potential glucocorticoid response elements ("GREs") (nucleotides 6148-6153, 6226-6231, 6247-6252, 6336-6341, 6510-6515, 6552-6557, 6727-6732, 6752-6757, 7738-7743, and 8255-8260), twelve potential Sma-2 homologues to Mothers against Drosophilla decapentaplegic ("SMAD") binding element sites (nucleotides 3569-3575, 4552-4558, 4582-4588, 5226-5232, 6228-6234, 6649-6655, 6725-6731, 6930-6936, 7379-7384, 7738-7742, 8073-8079, and 8378-8384), and three TATA boxes (nucleotides 5910-5913, 6932-6935, and 7380-7383). The three TATA boxes, all of the GREs, and eight of the SMAD binding elements ("SBEs") are grouped in the region spanning nucleotides 5,841-8,733 in SEQ ID NO: 41. These regulatory elements can be used, for example, to regulate expression of exogenous nucleotide sequences encoding proteins involved in the process of bone formation. This would permit systemic administration of therapeutic factors or genes relating to bone formation and repair, as well as factors or genes associated with tissue differentiation and development.

[0145] In addition to the putative regulatory elements, 13 exons corresponding to the nucleotide sequence encoding HLMP-1 have been identified. These exons span the following nucleotides in SEQ ID NO: 41:

Exon 1	8733-8767
Exon 2	9790-9895
Exon 3	13635-13787
Exon 4	13877-13907
Exon 5	14387-14502
Exon 6	15161-15297
Exon 7	15401-15437
Exon 8	16483-16545
Exon 9	16689-16923
Exon 10	18068-18248
Exon 11	22117-22240
Exon 12	22323-22440
Exon 13	22575-22911

[0146] In HLMP-2 there is another exon (Exon 5A), which spans nucleotides 14887-14904.

[0147] All cited publications and patents are hereby incorporated by reference in their entirety.

[0148] While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be appreciated by one skilled in the art from reading this disclosure that various changes in form and detail can be made without departing from the true scope of the invention.

SEQUENCE LISTING

5 <110> Boden M.D., Scott D
Hair Ph.D., Gregory A

<120> LIM Mineralization Protein Splice Variants

10 <130> splice variant LMP

<140> 6148.0222-00304
<141> 2000-04-28

15 <150> 60/132,021
<151> 1999-04-30

<160> 42

20 <170> PatentIn Ver. 2.1

<210> 1
<211> 457
<212> PRT
<213> Rattus norvegicus

25 <400> 1
Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

30 Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

35 Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

40 Leu Ser Arg Ala Gln Pro Ala Gln Ser Lys Pro Gln Lys Ala Leu Thr
85 90 95

Pro Pro Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Ala Ser Leu
100 105 110

45 Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Thr Asp Ser Ala
115 120 125

50 Leu Ser Gln Asn Gly Gln Leu Leu Arg Gln Leu Val Pro Asp Ala Ser
130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145 150 155 160

EP 1 808 182 A1

	Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr	
	165	170 175
5	Glu Phe Met Gln Asp Pro Asp Glu Glu Phe Met Lys Lys Ser Ser Gln	
	180	185 190
	Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Thr Ile Pro Gln Glu	
	195	200 205
10	Ser Trp Pro Gly Pro Thr Thr Pro Ser Pro Thr Ser Arg Pro Pro Trp	
	210	215 220
	Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser	
15	225	230 235 240
	Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln	
	245	250 255
	Asn Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Gly Thr Gly Gly	
20	260	265 270
	Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Ile	
	275	280 285
25	Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu	
	290	295 300
	Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe	
	305	310 315 320
30	Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Ser Cys Tyr Asp Val Arg	
	325	330 335
	Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile	
35	340	345 350
	Met His Ala Leu Lys Met Thr Trp His Val Pro Cys Phe Thr Cys Ala	
	355	360 365
	Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly	
40	370	375 380
	Ala Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys	
	385	390 395 400
45	Arg Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala	
	405	410 415
	Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln	
	420	425 430
50	Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Lys Pro Leu	
	435	440 445
	Cys Lys Ser His Ala Phe Ser His Val	
55	450	455

<210> 2
 <211> 1696
 <212> DNA
 <213> Rattus norvegicus

<400> 2
 gcacgaggat cccagcgcg ctcctggagg ccgccaggca gccgcccagc cgggcattca 60
 ggagcaggta ccatggattc cttcaaggta gtgctggagg gacctgccc ttggggcttc 120
 cgtctgcaag ggggcaagga cttcaacgtg cccctctcca tctctcggt cactcctgga 180
 ggcaaggccg cacaggccgg tgtggccgtg ggagactggg tactgagtat cgacgggtgag 240
 aacgccggaa gcctcacaca cattgaagcc cagaacaaga tccgtgctg tggggagcgc 300
 ctcagcctgg gtcttagcag agcccagcct gctcagagca aaccacagaa ggccctgacc 360
 cctcccgccg acccccagag gtacactttt gcaccaagcg cctccctcaa caagacggcc 420
 cggcccttcg gggcaccccc acctactgac agcgccctgt cgcagaatgg acagctgctc 480
 agacagctgg tccctgatgc cagcaagcag cggctgatgg agaatactga agactggcgc 540
 ccgcgccag ggacaggcca gtcccgttcc ttccgcatcc ttgctcacct caggggcaca 600
 gagttcatgc aagaccggga tgaggaattc atgaagaagt caagccagggt gcccaggaca 660
 gaagccccag cccagcctc aaccataccc caggaatcct ggcctggccc caccaccccc 720
 agccccacca gccgcccacc ctgggcccga gatectgcat ttgctgagcg ctatgcccc 780
 gacaaaacca gcacagtgt gaccgcacac agccagccag ccacacctac gcctctgcag 840
 aaccgcacct ccatagttca ggctgcagct ggagggggca caggaggagg cagcaacaat 900
 ggcaagacgc ctgtatgcca ccagtgccac aagatcatcc gcggccgata cctggtagca 960
 ctgggccacg cgtaccatcc tgaggaattt gtgtgcagcc agtgtgggaa ggtcctggaa 1020
 gaggggtggct tcttcgagga gaaggagct atcttttgcc cctcctgcta tgatgtgcgc 1080
 tatgcacca gctgtgcaa atgcaagaag aagatcactg gagagatcat gcatgcgctg 1140
 aagatgacct ggcattgtcc ctgcttacc tgtgcagcct gcaaaacccc tatccgcaac 1200
 agggctttct acatggagga gggggctccc tactgcgagc gagattacga gaagatgttt 1260
 ggcacaaagt gtgcggctg tgacttcaag atcgatgccg gggaccgttt cctggaagcc 1320
 ctgggtttca gctggcatga tacgtgtttt gtttgcgcaa tatgtcaaat caacttgga 1380
 ggaaagacct tctactcaa gaaggacaag cccctgtgca agagccatgc cttttccac 1440
 gtatgagcac ctctcacac tactgccacc ctactctgcc agaagggtga taaaatgaga 1500
 gagctctctc tccctcgacc tttctgggtg gggtggcag ccattgtcct agccttggt 1560
 cctggccaga tctggggct cctcctcac agtcccctt cccacacttc ctccaccacc 1620
 accaccgtca ctcacaggtg ctagectcct agccccagtt cactctggtg tcacaataaa 1680
 cctgtatgta gctgtg 1696

<210> 3
 <211> 260
 <212> DNA
 <213> Rattus norvegicus

<400> 3
 ttctacatgg aggagggggc tccctactgc gagcgagatt acgagaagat gtttggcaca 60
 aagtgtcgcg gctgtgactt caagatcgat gccggggacc gtttcttgga agccctgggt 120
 ttcagctggc atgatacgtg ttttgtttgc gcaatatgtc aaatcaactt ggaaggaaag 180
 accttctact ccaagaagga caagcccctg tgcaagagcc atgccttttc ccacgtatga 240
 gcacctctc acactactgc 260

<210> 4
 <211> 16
 <212> DNA
 <213> MMLV

EP 1 808 182 A1

<400> 4
aagctttttt tttttg 16

5
<210> 5
<211> 13
<212> DNA
<213> MMLV

10
<400> 5
aagcttggt atg 13

15
<210> 6
<211> 223
<212> DNA
<213> Homo sapiens

20
<400> 6
atccttgctc acctcacggg caccgagttc atgcaagacc cggatgagga gcacctgaag 60
aaatcaagcc aggtgcccag gacagaagcc ccagccccag cctcatctac accccaggag 120
ccctggcctg gccctaccgc ccccagccct accagccgcc cgccctgggc tgtggaccct 180
gcgtttgccc agcgctatgc cccagacaaa accagcacag tgc 223

25
<210> 7
<211> 717
<212> DNA
<213> Homo sapiens

30
<400> 7
atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctccctggggg caaagcggcg 120
caggccggag tggcgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgcct cagcctgggc 240
35 ctcagcaggg cccagccggt tcagagcaaa ccgcagaagg cctccgcccc cgccgcggac 300
cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccc gccctttggg 360
gcgcccccg cgcgtgacag cgccccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgcc a gcaagcagcg gctgatggag aacacagagg actggcggcc gcggccgggg 480
acaggccagt cgcgttcctt ccgcatecct gccacactca caggcaccga gttcatgcaa 540
40 gaccgggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacacccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
cgcccgccct gggctgtgga ccctgcgttt gccgagcgt atgccccga caaaacg 717

45
<210> 8
<211> 1488
<212> DNA
<213> Homo sapiens

50
<400> 8
atcgatggcg agaatgcggg tagcctcaca cacatcgaag ctcaagaaca gatccggggc 60
tgccggggagc gcctcagcct gggcctcagc agggcccagc cggttcagag caaaccgcag 120
aaggcctccg cccccgccgc ggaccctccg cggtagacct ttgcacccag cgtctccctc 180
aacaagacgg cccggccctt tggggcgccc ccgcccgtg acagcgcccc gcaacagaat 240
55 ggacagccgc tccgaccgct ggtcccagat gccagcaagc agcggctgat ggagaacaca 300

EP 1 808 182 A1

5
 10
 15
 20

```

gaggactggc ggccgcggcc ggggacaggc cagtcgcgtt ccttcgcgat ccttgcccac 360
ctcacaggca ccgagttcat gcaagacccg gatgaggagc acctgaagaa atcaagccag 420
gtgcccagga cagaagcccc agccccagcc tcatctacac cccaggagcc ctggcctggc 480
cctaccgccc ccagccctac cagccgcccg ccctgagctg tggaccctgc gtttgccgag 540
cgctatgccc cggacaaaac gagcacagtg ctgacccggc acagccagcc ggccacgccc 600
acgccgctgc agagccgcac ctccattgtg caggcagctg cgggaggggt gccaggaggg 660
ggcagcaaca acggcaagac tcccgtgtgt caccagtgc acaaggatcat ccggggccgc 720
tacctggtgg cgttggggcca cgcgtaccac ccggaggagt ttgtgtgtag ccagtgtggg 780
aaggctcctgg aagaggggtg cttctttgag gagaagggcg ccatcttctg cccaccatgc 840
tatgacgtgc gctatgcacc cagctgtgcc aagtgcaga agaagattac aggcgagatc 900
atgcacgccc tgaagatgac ctggcacgtg cactgcttta cctgtgctgc ctgcaagacg 960
cccatccgga acagggcctt ctacatggag gagggcgtgc cctattgcga gcgagactat 1020
gagaagatgt ttggcacgaa atgccatggc tgtgacttca agatcgacgc tggggaccgc 1080
ttcctggagg ccctgggctt cagctggcat gacacctgct tcgtctgtgc gatatgtcag 1140
atcaacctgg aaggaaagac cttctactcc aagaaggaca ggctctctg caagagccat 1200
gccttctctc atgtgtgagc cccttctgcc cacagctgcc gcggtggccc ctacgctgag 1260
gggcctggag tcgtggccct gcatttctgg gtagggctgg caatggttgc cttaacctg 1320
gctcctggcc cgagcctggg ctcccgggcc cctgccacc caccttatcc tcccaccca 1380
ctccctccac caccacagca caccggtgct ggccacacca gcccccttc acctccagt 1440
ccacaataaa cctgtaccca gctgaattcc aaaaaatcca aaaaaaaa 1488
  
```

25
 30

```

<210> 9
<211> 1644
<212> DNA
<213> Homo sapiens
  
```

35
 40
 45
 50
 55

```

<400> 9
atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctctggggg caaagcgggc 120
caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
ctcacacaca tcgaagctca gaacaagatc cgggcctgcg gggagcgctt cagcctgggc 240
ctcagcaggg ccagccgggt tcagagcaaa ccgcagaagg cctccgcccc cgccgcggac 300
cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccg gccctttggg 360
gcgccccgc ccgctgacag cgcgccgcaa cagaatggac agccgctccg accgctggtc 420
ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcggcc gcggccgggg 480
acaggccagt cgcgttcctt ccgcctcctt gccacctca caggcaccga gttcatgcaa 540
gacccggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
ccagcctcat ctacaccca ggagccctgg cctggcccta ccgccccag cctaccagc 660
cgcccgccct gggctgtgga ccctgcgttt gccgagcgct atgccccgga caaaacgagc 720
acagtgtgta ccggcacag ccagccggcc acgcccacgc cgctgcagag ccgcacctcc 780
attgtgcagg cagctgccgg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
gtgtgtcacc agtgccacaa ggtcatccgg ggccgctacc tgggtggcgtt gggccacgcg 900
taccacccgg aggagtttgt gtgtagccag tgtgggaagg tcctggaaga ggggtggcttc 960
tttgaggaga agggcgccat cttctgcca ccatgctatg acgtgcgcta tgcaccagc 1020
tgtgccaaat gcaagaagaa gattacaggc gagatcatgc acgccctgaa gatgacctgg 1080
cacgtgcact gctttacctg tgctgcctgc aagacgcca tccggaacag ggccttctac 1140
atggaggagg gcgtgcctta ttgcgagcga gactatgaga agatgtttgg cacgaaatgc 1200
catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggcttcagc 1260
tggcatgaca cctgcttcgt ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
tctgccaca gctgcgcggg tgccccctag cctgaggggc ctggagtcgt ggccctgcac 1440
tctgggtag ggctggcaat ggttgctta accctggctc ctggcccag cctgggctcc 1500
cgggcccctg cccaccacc ttatctccc accccactcc ctccaccacc acagcacacc 1560
ggtgctggcc acaccagccc cctttcacct ccagtgcac aataaacctg taccagctg 1620
aattcaaaa aatcaaaaa aaaa 1644
  
```

EP 1 808 182 A1

<210> 10

<211> 457

<212> PRT

<213> Homo sapiens

<400> 10

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
85 90 95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
115 120 125

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
165 170 175

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
180 185 190

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
195 200 205

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp
210 215 220

Ala Val Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser
225 230 235 240

Thr Val Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln
245 250 255

Ser Arg Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly

EP 1 808 182 A1

	260	265	270	
5	Gly Ser Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Lys Val 275 280 285			
	Ile Arg Gly Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu 290 295 300			
10	Glu Phe Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe 305 310 315 320			
	Phe Glu Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg 325 330 335			
15	Tyr Ala Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile 340 345 350			
	Met His Ala Leu Lys Met Thr Trp His Val His Cys Phe Thr Cys Ala 355 360 365			
20	Ala Cys Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly 370 375 380			
	Val Pro Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys 385 390 395 400			
25	His Gly Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala 405 410 415			
	Leu Gly Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln 420 425 430			
30	Ile Asn Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu 435 440 445			
35	Cys Lys Ser His Ala Phe Ser His Val 450 455			
40	<210> 11 <211> 22 <212> DNA <213> Rattus norvegicus			
45	<400> 11 gccagggttt tccagtcac ga			22
50	<210> 12 <211> 22 <212> DNA <213> Rattus norvegicus			
55	<400> 12 gccagggttt tccagtcac ga			22

5	<210> 13 <211> 22 <212> DNA <213> Homo sapiens	
10	<400> 13 tcttagcaga gccagcctg ct	22
15	<210> 14 <211> 22 <212> DNA <213> Homo sapiens	
20	<400> 14 gcatgaactc tgtgccctg ag	22
25	<210> 15 <211> 20 <212> DNA <213> Rattus norvegicus	
30	<400> 15 atccttgctc acctcacggg	20
35	<210> 16 <211> 22 <212> DNA <213> Rattus norvegicus	
40	<400> 16 gcactgtgct ggttttgtct gg	22
45	<210> 17 <211> 23 <212> DNA <213> Homo sapiens	
50	<400> 17 catggattcc ttcaaggtag tgc	23
55	<210> 18 <211> 20 <212> DNA <213> Homo sapiens	
	<400> 18 gttttgtctg gggcagagcg	20
	<210> 19 <211> 44	

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: adaptor for
Marathon RACE reactions

<400> 19
ctaatacgcac tcaactatagg gctcgaacccg ccgccccgggc aggt 44

```
<210> 20
<211> 27
<212> DNA
<213> Artificial Sequence
```

<220>
<223> Description of Artificial Sequence: PCR primer
specific for Marathon RACE adaptor

```
<400> 20
ccatcctaatacgaactcactatagggc 27
```

```
<210> 21
<211> 765
<212> DNA
<213> Homo sapiens
```

400							21
ccgttggtttg	taaaacgcagc	cagagcagcgc	ccctggccgcg	gccaaagcagg	agccggcatc		60
atggatttcct	tcaaggtagtc	gctggaggggg	ccagcacctt	ggggcttcgc	gctgcaagg		120
ggcaaggact	tcaatgtgcc	ctctccatt	tcccggtca	cctctggggg	caaggccgtg		180
caggccggag	tggccgtaag	tgactgggtg	ctgagcatcg	atggcgagaa	tgccggtagc		240
ctcacacaca	tcgaagctca	gaacaagatc	cgggcctgcg	gggagcgcct	cagcctgggc		300
ctcaacaggg	ccagccgggt	tcagaacaaa	ccgcaaaagg	cctccgcccc	cgcccgccgac		360
cctccgcggt	acacctttgc	accaagcgtc	tccctcaaca	agacggcccc	gccttggggg		420
gcgccccgc	ccgtgacag	cgccccgcag	cagaatggac	agccgctccg	accgctggtc		480
ccagatgcc	gcaagcagcg	gctgatggag	aacacagagg	actggccggc	gcggccgggg		540
acaggccagt	gccgttcctt	tcgcatacct	gtcacctta	caggcaccca	gttcattgaa		600
gaccgccgatg	aggagcacct	gaagaaatca	agccagggtgc	ccaggacaga	agccccagcc		660
ccagccctcat	ctacacccca	ggagccctgg	cctggcccta	ccggccccag	ccctaccagc		720
cgcccccct	gggctgtgga	ccctgcgttt	gccgagccct	atgcc			765

```
<210> 22
<211> 1689
<212> DNA
<213> Homo sapiens
```

```
<400> 22
cgacgcagag  cagcgccctg  gccggggcaa  gcaggagccg  gcatcatgga  ttccttcaag  60
gtagtgtctgg agggggccagc accttggggc  ttccggctgc  aagggggcaa  ggacttcaat  120
gtgcccctct  ccatttcccg  gctcactcct  gggggcaaag  cggcgcaggc  cggagtggcc  180
gtgggtgact  ggggtgtgag  catcgatggc  gagaatgcgg  gtacctcac  acacatcgaa  240
gctcagaaca  agatccgggc  ctgcggggag  cgcctcagcc  tgggcctcag  cagggcccaq  300
```

5 ccggttcaga gcaaaccgca gaaggcctcc gcccccgccg cggaccctcc gcggtacacc 360
 tttgcaccca gcgtctccct caacaagacg gcccgccctt ttggggcgcc cccgcccgt 420
 gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtcccaga tgccagcaag 480
 cagcggtga tggagaacac agaggactgg cggcccgccg cggggacagg ccagtccgt 540
 tccttcgcga tccttgccca cctcacaggc accgagttca tgcaagacct ggatgaggag 600
 cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcatctaca 660
 cccagggagc cctggcctgg ccctaccgcc ccagcccta ccagccgcc gcctggggt 720
 gtggaccctg cgtttgccga gcgtatgcc ccggacaaaa cgagcacagt gctgaccgg 780
 10 cacagccagc cggccacgcc cagccgctg cagagccgca cctccattgt gcaggcagct 840
 gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccggtg tcaccagtgc 900
 cacaagggtca tccggggccg ctacctggtg gcgttgggccc acgcgtacca cccggaggag 960
 tttgtgtgta gccagtgtgg gaaggctctg gaagagggtg gcttctttga ggagaagggc 1020
 gccatcttct gccaccatg ctatgacgtg cgctatgcac ccagctgtgc caagtgaag 1080
 15 aagaagatta caggcgagat catgcacgcc ctgaagatga cctggcacgt gcactgcttt 1140
 acctgtgctg cctgcaagac gcccatccgg aacagggcct tctacatgga ggagggcggtg 1200
 ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
 aagatcgacg ctgggggaccg cttcctggag gccctgggct tcagctggca tgacacctgc 1320
 ttggtctgtg cgatatgtca gatcaacctg gaaggaaaga cttctactc caagaaggac 1380
 20 aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
 cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcatctctg ggtagggctg 1500
 gcaatggttg ccttaacctt ggctcctggc ccgagcctgg gctcccgggc ccctgccac 1560
 ccaccttacc ctcccacccc actccctcca ccaccacagc acaccgggtg tggccacacc 1620
 agcccccttt cacctccagt gccacaataa acctgtacct agctgaattc caaaaaatcc 1680
 aaaaaaaaaa 1689

25

<210> 23

<211> 22

<212> DNA

<213> Homo sapiens

30

<400> 23

gcactgtgct cgttttgtcc gg

22

35

<210> 24

<211> 21

<212> DNA

<213> Homo sapiens

40

<400> 24

tccttgctca cctcacgggc a

21

<210> 25

<211> 30

<212> DNA

<213> Homo sapiens

45

<400> 25

tcctcatccg ggtcttgcat gaactcggtg

30

50

<210> 26

<211> 28

<212> DNA

55

<213> Homo sapiens
 <400> 26
 5 gcccccgccc gctgacagcg ccccgcaa 28
 <210> 27
 <211> 24
 10 <212> DNA
 <213> Homo sapiens
 <400> 27
 15 tccttgctca cctcacgggc accg 24
 <210> 28
 <211> 22
 <212> DNA
 20 <213> Homo sapiens
 <400> 28
 gtaatacgac tcactatagg gc 22
 <210> 29
 <211> 23
 <212> DNA
 25 <213> Rattus norvegicus
 <400> 29
 30 gcggctgatg gagaatactg aag 23
 <210> 30
 <211> 23
 <212> DNA
 35 <213> Rattus norvegicus
 <400> 30
 40 atcttggtggc actggtggca tac 23
 <210> 31
 <211> 22
 <212> DNA
 45 <213> Rattus norvegicus
 <400> 31
 tgtgtcgggt cagcactgtg ct 22
 <210> 32
 <211> 1620
 <212> DNA
 50 <213> Homo sapiens
 55

<400> 32

atggattcct tcaaggtagt gctggagggg ccagcacctt ggggcttccg gctgcaaggg 60
 ggcaaggact tcaatgtgcc cctctccatt tcccggctca ctcttggggg caaagcggg 120
 caggccggag tggccgtggg tgactgggtg ctgagcatcg atggcgagaa tgcgggtagc 180
 ctcacacaca tccaagctca gaacaagatc cgggcctgcg gggagcgctt cagcctgggc 240
 ctcatcaggg ccagccgggt tcagagcaaa ccgcagaagg cctccgcccc cgcccgggac 300
 cctccgcggt acacctttgc acccagcgtc tccctcaaca agacggcccc gccctttggg 360
 gcgccccgc ccgctgacag cgccccgcaa cagaatggac agccgctccg accgctggtc 420
 ccagatgcca gcaagcagcg gctgatggag aacacagagg actggcgggc gggccgggg 480
 acaggccagt cgcgttcctt ccgcatcctt gccacctca caggcaccga gttcatgcaa 540
 gacccggatg aggagcacct gaagaaatca agccaggtgc ccaggacaga agccccagcc 600
 ccagcctcat ctacaccca ggagccctgg cctggcccta ccgccccag ccctaccagc 660
 cgcccgccct gagctgtgga ccctgcgttt gccgagcgct atgccccgga caaaacgagc 720
 acagtgtgta ccgggcacag ccagccggcc acgcccacgc cgctgcagag ccgcacctcc 780
 attgtgcagg cagctgccgg aggggtgcca ggagggggca gcaacaacgg caagactccc 840
 gtgtgtcacc agtgccaaa ggtcatccgg ggccgctacc tgggtggcgtt gggccacgcg 900
 taccacccgg aggagtttgt gtgtagccag tgtgggaagg tcctggaaga ggggtgcttc 960
 tttgaggaga agggcgccat cttctgccc ccatgctatg acgtgcgcta tgcaccagc 1020
 tgtgccaagt gcaagaagaa gattacaggc gagatcatgc acgccctgaa gatgacctgg 1080
 cagtgcaact gctttacctg tgctgcctgc aagacgccc tccggaacag ggccttctac 1140
 atggaggagg gcggtgcccta ttgcgagcga gactatgaga agatgtttgg cacgaaatgc 1200
 catggctgtg acttcaagat cgacgctggg gaccgcttcc tggaggccct gggcttcagc 1260
 tggcatgaca cctgcttcgt ctgtgcgata tgtcagatca acctggaagg aaagaccttc 1320
 tactccaaga aggacaggcc tctctgcaag agccatgcct tctctcatgt gtgagccct 1380
 tctgcccaca gctgcgcggg tggcccttag cctgaggggc ctggagtcgt ggccttgcac 1440
 ttctgggtag ggctggcaat ggttgcccta accctggctc ctggcccgag cctgggctcc 1500
 cgggcccctg ccacccacc ttatcctccc accccactcc ctccaccacc acagcacacc 1560
 ggtgctggcc acaccagccc cctttcacct ccagtgccac aataaacctg taccagctg 1620

<210> 33

<211> 1665

<212> DNA

<213> Homo sapiens

<400> 33

cgacgcagag cagcgccctg gccgggcca a gcaggagccg gcatcatgga ttccttcaag 60
 gtagtgtctg agggggccagc accttggggc ttcgggctgc aagggggcaa ggacttcaat 120
 gtgccccctc ccatttccc gctcactcct gggggcaaa cggcgaggc cggagtggcc 180
 gtgggtgact ggggtgctgag catcgatggc gagaatgcgg gtagcctcac acacatcgaa 240
 gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag caggggccag 300
 ccggttcaga gcaaaccgca gaaggcctcc gccccgcgg cggacctcc gcggtacacc 360
 tttgcaccca gcgtctccct caacaagacg gcccgccct ttggggcgcc cccgcccgt 420
 gacagcgccc cgcaacagaa tggacagccg ctccgaccgc tgggtcccaga tgccagcaag 480
 cagcggctga tggagaacac agaggactgg cggcccgggc cggggacagg ccagtgcgct 540
 tccttccgca tccttgccca cctcacaggc accgagttca tgcaagacct ggatgaggag 600
 cacctgaaga aatcaagcca ggtgcccagg acagaagccc cagccccagc ctcatctaca 660
 cccagaggag cctggcctgg ccttaaccgc ccagcccta ccagccgccc gccctgagct 720
 gtggaccctg cgtttgcca gcgctatgcc ccggacaaa cgagcacagt gctgaccgg 780
 cacagccagc cggccacgcc cagcgcgctg cagagccgca cctccattgt gcaggcagct 840
 gccggagggg tgccaggagg gggcagcaac aacggcaaga ctcccgtgtg tcaccagtgc 900
 cacaaggtca tccggggccg ctacctggtg gcgttgggccc acgcgtacca cccggaggag 960
 tttgtgtgta gccagtgtgg gaaggtcctg gaagagggtg gcttctttga ggagaagggc 1020
 gccatcttct gccaccatg ctatgacgtg cgctatgcac ccagctgtgc caagtgcag 1080
 aagaagatta caggcgagat catgcagccc ctgaagatga cctggcacgt gcaactgctt 1140
 acctgtgctg cctgcaagac gcccatccgg aacagggcct tctacatgga ggaggcgctg 1200

EP 1 808 182 A1

ccctattgcg agcgagacta tgagaagatg tttggcacga aatgccatgg ctgtgacttc 1260
aagatcgacg ctgggggaccg cttcctggag gccctgggct tcagctggca tgacacctgc 1320
ttcgtctgtg cgatatgtca gatcaacctg gaaggaaaga ccttctactc caagaaggac 1380
aggcctctct gcaagagcca tgccttctct catgtgtgag ccccttctgc ccacagctgc 1440
cgcggtggcc cctagcctga ggggcctgga gtcgtggccc tgcatttctg ggtagggctg 1500
gcaatggttg ccttaaccct ggctcctggc ccgagcctgg gctcccgggc ccctgcccac 1560
ccaccttacc cteccacccc actccctcca ccaccacagc acaccggtgc tggccacacc 1620
agcccccttt cacctccagt gccacaataa acctgtaccc agctg 1665

<210> 34

<211> 223

<212> PRT

<213> Homo sapiens

<400> 34

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
85 90 95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
115 120 125

Pro Gln Gln Asn Gly Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser
130 135 140

Lys Gln Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly
145 150 155 160

Thr Gly Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr
165 170 175

Glu Phe Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln
180 185 190

Val Pro Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu
195 200 205

Pro Trp Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro

EP 1 808 182 A1

	210	215	220
5	<210> 35 <211> 20 <212> DNA <213> Homo sapiens		
10	<400> 35 gagccggcat catggattcc		
			20
15	<210> 36 <211> 20 <212> DNA <213> Homo sapiens		
20	<400> 36 gctgcctgca caatggaggt		
			20
25	<210> 37 <211> 1456 <212> DNA <213> Homo sapiens		
30	<400> 37 cgacgcagag cagcgccctg gccgggcca gacggagccg gcatcatgga ttccttcaag 60 gtagtgctgg aggggccagc accttggggc ttccggctgc aagggggcaa ggacttcaat 120 gtgcccctct ccatttccc gctcactoct gggggcaag cggcgagggc cggagtggcc 180 gtgggtgact gggtgctgag catcgatggc gagaatgcgg gtacgctcac acacatcgaa 240 gctcagaaca agatccgggc ctgcggggag cgctcagcc tgggcctcag caggggccag 300 ccggttcaga gcaaaccgca gaaggtgcag acccctgaca aacagccgct ccgaccgctg 360 gtcccagatg ccagcaagca gcggctgatg gagaacacag aggactggcg gccgcggccg 420 gggacaggcc agtcgcgttc cttccgcata cttgcccacc tcacaggcac cgagtcatg 480 caagaccggt atgaggagca cctgaagaaa tcaagccagg tgcccaggac agaagcccca 540 gcccagcct catctacacc ccaggagccc tggcctggcc ctaccgcccc cagccctacc 600 agccgcccgc cctgggctgt ggaccctgcg tttgcgagc gctatgcccc ggacaaaacg 660 agcacagtgc tgaccggca cagccagccg gccacgccc cgccgctgca gagccgcacc 720 tccattgtgc aggcagctgc cggaggggtg ccaggagggg gcagcaacaa cggcaagact 780 cccgtgtgtc accagtgcc caaggtcatc cggggccgct acctggtggc gttggggcac 840 gcgtaccacc cggaggagtt tgtgtgtagc cagtgtggga aggtcctgga agaggggtggc 900 ttctttgagg agaagggcgc catcttctgc ccaccatgct atgacgtgcg ctatgcaccc 960 agctgtgcca agtgcaagaa gaagattaca ggcgagatca tgcacgccc gaagatgacc 1020 tggcacgtgc actgctttac ctgtgctgcc tgcaagacgc ccacccggaa cagggccttc 1080 tacatggagg agggcgctgc ctattgagag cgagactatg agaagatgtt tggcacgaaa 1140 tgccatggct gtgacttcaa gatcgacgct ggggaccgct tcctggaggc cctgggcttc 1200 agctggcatg acacctgctt cgtctgtgcg atatgtcaga tcaacctgga aggaaagacc 1260 ttctactcca agaaggacag gcctctctgc aagagccatg ccttctctca tgtgtgagcc 1320 ccttctgccc acagctgccg cgggtggccc tagcctgagg ggccctggag cgtggccctg 1380 catctctggg tagggctggc aatggttgcc ttaacctgg ctccctggcc gagcctgggc 1440 tcccgggccc tgccca		
35			1456
40	<210> 38 <211> 423		
45			
50			
55			

EP 1 808 182 A1

<212> PRT

<213> Homo sapiens

5

<400> 38

Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
1 5 10 15

10

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
35 40 45

15

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
65 70 75 80

20

Leu Ser Arg Ala Gln Pro Val Gln Asn Lys Pro Gln Lys Val Gln Thr
85 90 95

Pro Asp Lys Gln Pro Leu Arg Pro Leu Val Pro Asp Ala Ser Lys Gln
100 105 110

25

Arg Leu Met Glu Asn Thr Glu Asp Trp Arg Pro Arg Pro Gly Thr Gly
115 120 125

Gln Ser Arg Ser Phe Arg Ile Leu Ala His Leu Thr Gly Thr Glu Phe
130 135 140

30

Met Gln Asp Pro Asp Glu Glu His Leu Lys Lys Ser Ser Gln Val Pro
145 150 155 160

35

Arg Thr Glu Ala Pro Ala Pro Ala Ser Ser Thr Pro Gln Glu Pro Trp
165 170 175

Pro Gly Pro Thr Ala Pro Ser Pro Thr Ser Arg Pro Pro Trp Ala Val
180 185 190

40

Asp Pro Ala Phe Ala Glu Arg Tyr Ala Pro Asp Lys Thr Ser Thr Val
195 200 205

Leu Thr Arg His Ser Gln Pro Ala Thr Pro Thr Pro Leu Gln Ser Arg
210 215 220

45

Thr Ser Ile Val Gln Ala Ala Ala Gly Gly Val Pro Gly Gly Gly Ser
225 230 235 240

Asn Asn Gly Lys Thr Pro Val Cys His Gln Cys His Gln Val Ile Arg
245 250 255

50

Ala Arg Tyr Leu Val Ala Leu Gly His Ala Tyr His Pro Glu Glu Phe
260 265 270

55

Val Cys Ser Gln Cys Gly Lys Val Leu Glu Glu Gly Gly Phe Phe Glu

EP 1 808 182 A1

275 280 285

5 Glu Lys Gly Ala Ile Phe Cys Pro Pro Cys Tyr Asp Val Arg Tyr Ala
290 295 300

Pro Ser Cys Ala Lys Cys Lys Lys Lys Ile Thr Gly Glu Ile Met His
305 310 315 320

10 Ala Leu Lys Met Thr Trp His Val Leu Cys Phe Thr Cys Ala Ala Cys
325 330 335

Lys Thr Pro Ile Arg Asn Arg Ala Phe Tyr Met Glu Glu Gly Val Pro
340 345 350

15 Tyr Cys Glu Arg Asp Tyr Glu Lys Met Phe Gly Thr Lys Cys Gln Trp
355 360 365

Cys Asp Phe Lys Ile Asp Ala Gly Asp Arg Phe Leu Glu Ala Leu Gly
370 375 380

20 Phe Ser Trp His Asp Thr Cys Phe Val Cys Ala Ile Cys Gln Ile Asn
385 390 395 400

25 Leu Glu Gly Lys Thr Phe Tyr Ser Lys Lys Asp Arg Pro Leu Cys Lys
405 410 415

Ser His Ala Phe Ser His Val
420

30 <210> 39
<211> 1575
<212> DNA
<213> Homo sapiens

35 <400> 39
cgacgcagag cagcgccctg gccgggcca gaggagccg gcatcatgga ttccttcaag 60
gtagtgctgg agggggccagc accttggggc ttccggctgc aagggggcaa ggacttcaat 120
gtgcccctct ccatttccc gctcactcct gggggcaaag cggcgaggc cggagtggcc 180
gtgggtgact ggggtgctgag catcgatggc gagaatgcg gtagcctcac acacatcgaa 240
40 gctcagaaca agatccgggc ctgcggggag cgcctcagcc tgggcctcag cagggcccag 300
ccgggttcaga gcaaaccgca gaaggcctcc gccccgcgc cggaccctcc gcggtacacc 360
tttgcaccca gcgtctccct caacaagacg gcccgccct ttggggcgcc cccgcccgc 420
gacagcgccc cgcaacagaa tgggtgcaga cccctgacaa acagccgctc cgaccgctgg 480
tcccagatgc cagcaagcag cggctgatgg agaacacaga ggactggcgg ccgcgggccg 540
45 ggacaggcca gtgcggttcc ttccgcatcc ttgccacct cacaggcacc gagttcatgc 600
aagacccgga tgaggagcac ctgaagaaat caagccaggt gccaggaca gaagccccag 660
ccccagcctc atctacaccc caggagccct ggcctggccc taccgcccc agccctacca 720
gccgcccgc ctgggctgtg gacctgcgt ttgccgagcg ctatgcccgc gacaaaacga 780
gcacagtgt gacctggcac agccagccgg ccacgcccac gccgctgcag agccgcacct 840
50 ccattgtgca ggcagctgcc ggaggggtgc caggaggggg cagcaacaac ggcaagactc 900
ccgtgtgtca ccagtgccac aaggctcatcc ggggcccgt cctgggtggc ttggggccacg 960
cgtaccaccc ggaggagttt gtgtgtagcc agtgtgggaa ggtcctggaa gagggtggct 1020
tctttgagaa gaagggcgcc atcttctgcc caccatgcta tgacgtgcgc tatgcacca 1080
gctgtgccaa gtgcaagaag aagattacag gcgagatcat gcacgccctg aagatgacct 1140
55 ggcacgtgca ctgctttacc tgtgtgcct gcaagacgcc catccggaac agggccttct 1200

EP 1 808 182 A1

acatggagga gggcgtgccc tattgcgagc gagactatga gaagatgttt ggcacgaaat 1260
 gccatggctg tgacttcaag atcgacgctg gggaccgctt cctggaggcc ctgggcttca 1320
 gctggcatga cacctgcttc gtctgtgcga tatgtcagat caacctggaa ggaaagacct 1380
 tctactccaa gaaggacagg cctctctgca agagccatgc cttctctcat gtgtgagccc 1440
 cttctgcccc cagctgccgc ggtggccctt agcctgaggg gcctggagtc gtggccctgc 1500
 atttctgggt agggctggca atggttgctt taaccctggc tcctggcccc agcctgggct 1560
 cccgggccct gccca 1575

<210> 40
 <211> 153
 <212> PRT
 <213> Homo sapiens

<400> 40
 Met Asp Ser Phe Lys Val Val Leu Glu Gly Pro Ala Pro Trp Gly Phe
 1 5 10 15

Arg Leu Gln Gly Gly Lys Asp Phe Asn Val Pro Leu Ser Ile Ser Arg
 20 25 30

Leu Thr Pro Gly Gly Lys Ala Ala Gln Ala Gly Val Ala Val Gly Asp
 35 40 45

Trp Val Leu Ser Ile Asp Gly Glu Asn Ala Gly Ser Leu Thr His Ile
 50 55 60

Glu Ala Gln Asn Lys Ile Arg Ala Cys Gly Glu Arg Leu Ser Leu Gly
 65 70 75 80

Leu Ser Arg Ala Gln Pro Val Gln Ser Lys Pro Gln Lys Ala Ser Ala
 85 90 95

Pro Ala Ala Asp Pro Pro Arg Tyr Thr Phe Ala Pro Ser Val Ser Leu
 100 105 110

Asn Lys Thr Ala Arg Pro Phe Gly Ala Pro Pro Pro Ala Asp Ser Ala
 115 120 125

Pro Gln Gln Asn Gly Cys Arg Pro Leu Thr Asn Ser Arg Ser Asp Arg
 130 135 140

Trp Ser Gln Met Pro Ala Ser Ser Gly
 145 150

<210> 41
 <211> 24740
 <212> DNA
 <213> Homo sapiens

<400> 41
 nnnnnntgta ttttatcata ttttaaaaat caaaaaacaa aaggcagttg aggttaggca 60
 tggaggttcg tgccctgtaat cccagcactt tgggaagccg aagcacgtgg atcacctgag 120
 gtcaggagtt cgagaccagc ctgcccataa tggtaaaacc ctgtctctac taaaaatata 180
 aaaaattagc caggcatggt ggtgggcacc tgtaatccca gctacttggg agactgaggc 240

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

aggagaaatca cttaaacccg ggaggcgggc tgggcgcggt ggctcatgcc tgtaatccca 300
 gcactttggg aggccgagac aggcggatca tgaggtcagg agatcgagat catcctggct 360
 aacatggtga aaccccatct ctactaaaaa tacaaaaaaa attagccagg cctggtggcg 420
 ggcacctgta gtcccagcta cttgggaggc tgaggcagga gaatggcgtg aacctgggag 480
 gcggcgttgc agtgagccaa gatcgcgcca ctgcactcca gcctggcgga caagagttag 540
 actccatctt aaagaaaaaa aacaaacccg ggaggcgga attgcagtca gccgagatct 600
 cgccattgca ctcaagtatg ggtgacagag caagactcca tgtcaaaaaa aaaggcagtt 660
 gacaggagca aggagcctgg tgaggaaagt gtggcatttg acccggtgtg gttgctatgg 720
 gccagggtgg tgctagtaga ggagctgagt gggaaagagc acaggggaca tgctgaaggc 780
 ctgggtgtgg ggatgaggca gagattgggg gcaccttgca gggtcatagc aggtggctgt 840
 ggtgagatgg aggaagacac ctgggggtact gctctaggct gtcagacata cagaagctgg 900
 cccagccaag cccaggggct gcaagggaca tccttttggt tccccagtga tctgcagctc 960
 tcagacaccc tcaagcacag tgcctcttgc ccagccagc actctcagtg gggagccagg 1020
 tgggagaaca ggctcggaag gggacctagg cttatgcagc gagccgggca aagctggaac 1080
 tggagcccag gccctgggat gccctctggc ttgtggagtt ctgggatact gaggggaggg 1140
 gacagggcat gggagtgcgg tgctctcacc tttgacttga actcattccc caggggacag 1200
 gggaggcctc ctccagatcc acagatgccc agtctcccaa gaggggcctg gtccccatgg 1260
 aggaaaactc catctactcc tcctggcagg aaggtaaagt ggaggacgtg caagggcagc 1320
 ctccagcccc cacaccagg gctgggtctt tttgggactg acggagctgt cctggccacc 1380
 tgccacagtg ggcgagtctc ccgtggtggt gcagaggact gagggcgcca cccgctgcca 1440
 gctgaagggg ccggccctgc tgggtgctggg ccagacgcc atccagctga gggagccaa 1500
 ggcacccagg cctctacag ctggccctac cacttctgc gcaagttcgg ctccgacaag 1560
 gtgaggtgca ggggtgggaa agggtagagg gctgacagcc tggaccctcc tgctaattcc 1620
 caccctgtgt cctgtgccc agggcgtgtt ctctttgag gccggcgtc gctgccactc 1680
 gggtaggggc ctctttgcct tcagcaccct ctgtgcccct gacctgtgca gggctgtggc 1740
 cggggcctac ccgcccagcg ggagcgctg ccagagctga ccaggcccca gccctgcccc 1800
 ctggccacgg ccacctctct gccctccctg gacaccccg gagagcttcg ggagatgcca 1860
 ccaggacctg agccaccac gtccaggaaa atgcacctgg ccgagcccg accccagagc 1920
 ctgccgtac tgctaggccc ggagcccaac gatctggcgt ccgggctcta cgcttcagtg 1980
 tgcaagcgtg ccagtgggccc ccaggcaat gagcacctct atgagaacct gtgtgtgctg 2040
 gagggcagcc ccacgtgca cgggtgggaa cctgagccgc acgagggccc cggcagccgc 2100
 agccccacaa ccagtcccat ctaccacaac ggccaggact tgagctggcc cggcccgccc 2160
 aacgacagta ccctggaggc ccagtaccgg cggctgtgtg agctggatca ggtggagggc 2220
 acaggccgcc ctgacctca ggcaggttct aaggccaagc tggtagccct gctgagctgt 2280
 gagcggagga agggcccagc ccctgtgac cggccctgaa cgcccagcag agtggtggcc 2340
 agaggggaga ggtgctcccc ctgggacagg aggggtgggt ggtgggcaaa cattggggcc 2400
 atgcagacac acgctgtgt ccacctggc ctgcaggaac aaggcaggcc gcctgtggag 2460
 gacctcagcc ctgccctgcc ctctcatga atagtgtgca gactcacaga taataaagct 2520
 cagagcagct ccggcaggg gcatcacgg cacacgccc tgcccaggtt cattgcggcc 2580
 aacacaagca ccctgtgccc gttccagggg cacaggtgac ctgggcctta cttgccacc 2640
 gtgggtctcaa acccactgca gcagacagac gggatggaaa tcattaggac tccatggtgc 2700
 tctgcacggc cgagtgcac gaagaggcag gcggaggagg ctgtgaggct tacttgtcag 2760
 actcaggaag gagcaacatg agggcccaac tggagacccg gagggccgag ctgggaggag 2820
 gcagtggggg cgggtgtag gtggaaggga tttcagagac accctcgtcc aaaacacttg 2880
 ttccctgctg aaactccaac aatttgaga tacttctggg aaccccaggc gtcagtctcc 2940
 tcactgttaa aggagagaga accgatgacg tatcaggcat aatccttgat gagagtgtgc 3000
 tgctgtccta ctcagtgcga ggcgtgggg gacacagccg tggtcaggac agccttggtc 3060
 ctgttctccg ggagccgaca ttccaggggg agagaagttt cctgaagact tccatgctgc 3120
 gttccctcct ctgctcctgc tcctggcgcc atcctaggag ccagccatgc acgcaagcgt 3180
 catgcctcca gggctctgac tgcccagccc ctcaccgcaa ctccacctca gctgcacaca 3240
 cccttggcac atcctgaacc tcattttcat gacggacaca caatttttgc tctctcctgt 3300
 ccaagcctca tcctctggcc gccacctcct tccagctcac ttcttttagt gcggccagta 3360
 ccggccctgc ctaggcatgt cgacctgcag ggacctttt ctggctcttc gaggcctctg 3420
 cccaccatcc cctctttgtt ctccatagtc ccttccccct gttctctctc gtttcatctt 3480
 actggtctgg caaagtcccc ggccttgggc gagccagacc tcctcagtgc ctgcacacag 3540
 ctgcccacag ccagagaaat ccatttaagc agactgcctg catccttctt aacagtgcaa 3600

5 ggcaggcact cectgccaca agagaccctg ttccctagta gggcagcttt tctcctccc 3660
 agaacctcct gtctatcccc acccaatgtc tcctcacagg catattgggg aaacagggtca 3720
 ggctctccca cegtatctgc aagtgtactg gcatccatct gtcttcttcc taccctaca 3780
 gtagaaacag tgtctgtccc cagctgtgct ctgatcccg ctcctttcac ctcagagctt 3840
 ggaaaattga gctgtcccca ctctctctct cgtccattca tectaccagc agcttttcca 3900
 gccacacgca aacatgctct gtaatttcac attttaaac ttcccttgac ctcacattcc 3960
 tcttcggcca cctctgttct tctgttctct ttacagcaa aaactgttca aaagagtgt 4020
 tgattacttt catttccact ttctcaccct cattctctcc tcaattaact ctcttccatc 4080
 10 cccatgatgc cattatgtgg cttttattag agtcaccaac cttattctcc aaaacaaaag 4140
 caacaaggac tttgacttct cagcagcact cagctctggt tcttgaaaca cccccgttac 4200
 ttgctattcc tctacctca taacaatctc cttcccagcc tctactgtg ccttctctga 4260
 gttcttccca gggctcctagg ctcagatgta gtgtagctca accctgctac acaaagaatc 4320
 tcctgaaagc ctgtaaaaaat gtccatgcat gttctgtgag tgatctacca agaaaataaa 4380
 15 aaatttttaa aatcaaatgc ccatgcctgg gccacacgc aggggctctg atttcatcag 4440
 tctggtaggt ggggttctggg catccacgct cactggattt ccggatgatt gtagtatgca 4500
 gcctaggctg ggaaccactg gcctcagcaa gccagtcatt ctccaggtgt cacagaccct 4560
 ctagggtgta atgaccccga aggtctgtct tcagtgcaca cctccccctg agctccagat 4620
 ttaggaatcc cactgcacac gagacatctg gatgtggaaa agacatctcc agatcccatg 4680
 20 ggtgaaaggg ggttggggga atggagactc gtgttcttcc aggatgtgtg tggacacaga 4740
 atgcaaagcc tggagggatg cttagagccat agggagggaag atttcggctc acttattcat 4800
 gcaagcactt cctgatgggt aaggtcttag agcaagctga ggccaagagg cgggcagtcg 4860
 aggtgctgct gcaggcacc cactcccta cagtggcaag cccaagcca gcccttgga 4920
 gctcaaatcc caggacacgc tgaaggctac ccagagagtc aggggcatgg ctgaaccag 4980
 aaccaggac tctggggacc cagcatggca tcttctctt cattacaaat ctgagctgct 5040
 25 ttgtttctta gggatttctg tgatattcca aggggactgt gggaaagaaa gtccttgga 5100
 accaccagga cgctagaggc ctggcctgga gcctcaggag tctcggccac cagagggcgc 5160
 tgggtccttg tccaggtcca gttgctacgc aggggctgcc tgtgctggga ggctcccag 5220
 gggacacaga ccagagcctt gcaccagccc aaggaatggg agcctggggc cctctctgct 5280
 ggaggactgc caggaccccc aggtgcccgc ctcttcttct gctcatttgc tgtttcactt 5340
 30 tgtcaatcct tcttcttctc gtgtgttcat tcacatccac tgtgtgctgg cctggggaa 5400
 atgttagata agacacatta gctgtgtgtc ttcatgttcc taacaaagaa cacacctgg 5460
 aaagagcacc gcagagagtc cccattcccc catctccctc cacacatgga atctggagat 5520
 gccttttcca catccagatg tctctggtgc tgtgggattc ttaaataaac aaacatttca 5580
 tacagaatgt gagatgatgg agatgctatg gggaaaagta aagcagaggg agggcctagt 5640
 35 gtgtgatgcg ggtgaggcat ccagggattg ctgtttcagc tgtgatcagg aaaggccctg 5700
 ggaggaggcc acatctgagc agagacctaa ataaagtgg aaacctgttg ctgagatata 5760
 tggagaagtg tttcaagggc cgggcaccgg gcctggtggc tcacgcctgt aatcccagca 5820
 ctttgggagg ccaaggcagg tggatcgtg aggtcagga gtttgagagc agcttgacca 5880
 acatggagaa acccatctc tactaaacat ataaaaatta tccgggcatg gtggttcatg 5940
 40 cctgtagtcc cagctactcg ggaggttgag gcaggagaat cacttgaacg tgggaggcag 6000
 aggttgacgc aagccgagat cacaccactg cactccagcc tggatgacag agcgagactc 6060
 cgtctcaaaa aaaaaaaga aaagaaaaaa gaaaaaaa gaaaagtgtt tcaagcaggg 6120
 gaactggcaa gtggagaggc cctgaggcag aaatatgctt ggctgctgg aggaaatgtg 6180
 agtgaggagg tcagggtggc tggagtggag ggagcgagt gtaggagtc gacccagttt 6240
 attcatattc ttaggtctt aaggacttca gttttatttt gagtgcata tgagccact 6300
 45 ggaatgctaa aagctgagag tgacatggtg ctgtgattct ggcttataaa atatcacttt 6360
 ggctgcttcg tgaagactct ggaaggggca aggtgaaag cagggatgcc cgttaggaga 6420
 ccgttacagg ggcgcaggca caaatggca gtggtggga caatggtggc agcagcgggt 6480
 agatgtgaac atgttgaagg tggaaatttg agaatctggg ggaggacaga agagaaagga 6540
 taacttcatc gtttctgctg aaccagtgg ataaatgttg gtggcacttc ttgaagtgg 6600
 50 gaaggagtta ggaaggtggg aaaggcaca gtttgaattg ggccatgatg gtctgagata 6660
 ctagtacag tggttcccca acctttttgg cagaagggac cgcttctcat gaagacaatt 6720
 ttccacaga ctgggggtgg ggtggggatg gtttcagggt ggttcgagt cagtacattt 6780
 atcattagac tctttttttt ttttttttct tgagatagag tctcgtctg tccccacac 6840
 tggagtgcag tggagccatc ttggctcaet acaacctctg ctgcccagg tcaagtcatt 6900
 55 ctctgcctc agcctctcaa gtgctggga ttataggcat atgcgccacc acgcccagct 6960

aattttttgta ttttttagtag agacgggggtt tcaccatatt ggccaggatg gtctcgaact 7020
 cctgacctca agtgatcctc ccccgccctca acctcccaaa gtgctgggggt tacaggcgtg 7080
 aaccactgca cccggcccat ttatcattag attctcataa ggaatgagca acctagatcc 7140
 5 ctcgcatgca cagttcacaa taggggttcac gctcctatgg gagtctaatag ctgccgctgc 7200
 actcagcttc tctggcttgc cgctgctcac ctctgctgt gcagcccagt tcctaacagg 7260
 ccacaaacgg ggagttgggg acccctgac tagtaaacat ctaggcaggg ttttgataa 7320
 tggagttaga gttcctgggg agaggtcagg ctggccatga aacatgggat gcctttgcat 7380
 ataggtggtg ttgaaagcca caggacagta cggggtctca gggggtgagc ataaagagag 7440
 10 gcgacatcag atggccaagg ccagaggcag aggaggatgg gaaggagggg ccagtggggc 7500
 agggggaagc tgtgaagcca gggaaaaagg gtgtttcgcg gaaaaggatc aacctggacc 7560
 agtgctgccc ctaggcaggg caggatgaaa cttaaccacc acggattcca tggcccatg 7620
 gcctccaggc cacaggggac cttgagaaga gagatctcag gggacgggtg cggacaagag 7680
 cccgcctggc atggcttcaa gagataactg aaggaaagca agtggagacg cgataaacag 7740
 15 acaactccct ggaggaattt tactctcgag aggagaatta aagggtagta gctggagagg 7800
 gatgtgggggt caagagaagg tctttaacga cgagaactct cacggcgggt tgtgcagaac 7860
 aggggtgggtg tgatgactgt ggatggagag gggagaactg cagcgactct gtcctaggag 7920
 gaggtgatgg gccgggacca ccaagcaggt ggaggggtga cggcccttcc ctcacccga 7980
 caccgcgatg tgctcagtgt ccgtgccgcc ggccctagtg cctgggctga acgcggggcc 8040
 20 gggactctga ggacgcctcc caggcgcgca gtccgtctgg ccaagggtga gcgggacggc 8100
 ngcttccgac ggtgcgcggg tcggctcggg gttgcaggga catccggcgt ccgctcctgc 8160
 cctgttttcc tgccctcgca gagcgttgcg caactctagc tttaaacgcc cctgtccccc 8220
 tcaacttgtc tccccagcc cctctgattt acagattctg cagtccccga ggggtgcgac 8280
 tacgataccg aactcgcgg cagcctgcga ggcagtatg atcgtcccat ttttcggagt 8340
 agcaaaactaa ggttcagaga ctactatgtc ccaggtcgggt ctggtttgaa ggtccgcttt 8400
 25 cctctccctc cgccagcggg cgggtgcgagg gactgggcga ggcagcgctt ccctaaggag 8460
 gcgacccgca gccccggccc cctcccgact ccgccccgtt gcagggcccg ggtcggcgag 8520
 gcctctcagc tctaagcccg acgggacttg gtgattgggc aggacggaag agctgggtgg 8580
 ggctttccac cagcggagaa agtctagtgg gcgtggtcgc gacgagggcg tggcctgggtg 8640
 ccccgccccc gtccgcgcgc tcaaagtggg ggggtgctgt gggggcgggg tcagaaact 8700
 30 ggcggccgat cccaacgagg ctccctggag cccgacgcag agcagcgccc tggccggggc 8760
 aagcagggtat cgacgaccgc gcggggcgctc ttgggttgga ccaggcgggc gcccgggggc 8820
 tgctgaggac cacaaagggc actgggggtc gtggtccagg ctgtgcttcc tcccgctggc 8880
 cctggccccc gctccgccc ccgccccgc cttcctgcgc ctaagccggc tcgcgccggg 8940
 ccgattggcg cctgcccgt tectgcgcg gggccagctc aatgcatggg gcccgggcg 9000
 35 gggactaagg ggaactgag tcacgtcgggt gtgggagcag ttctgtgtgg gaggaccac 9060
 cccccactgg gctcggggaa ggtccccct ccaagctatg cttgagggtc ccagccccc 9120
 tctgtctcca caggggcgc accccactcc cgccttccc ttcttcagca ccaggggtc 9180
 ccgcccctggc tcccagcagc ctcgactgggt ccgggaatgg ctaggaggat ccgctgcagc 9240
 cgcctccctc cctccccc cctccccc cctccccc cctccccc cctccccc 9300
 cccctcgcgt cccaagcccc cgtgtgctcc ctccgctggc tctccgcaca gtgtcagctt 9360
 40 acacgcctta tatagtcga gcaggctcca gcccgggcct gctgcgggga cctggggggc 9420
 ggggagagga gagccggccc ctgactcacc cggaccgccc gaggtccag gctggcttg 9480
 ggggagggcg cgccagttta gtccctcggc ccacccctgg ttgcaaagaa cctcaagcct 9540
 ggattcaggc acccctcacc gttccagtcc caaggggagg ggggctgctc ctgtctttcc 9600
 aaagtgaggt ccgccagcca gcagcccagg ccagcctgac aaaatacctg cctcctatgg 9660
 45 cttgggcgtg ctcaggggct gcccggtgct gcctggcccc tgtccaaggc tggatcctg 9720
 agctggcccg gcctgcctgc ctgcccgc accatgctgg ccactcacct tctcttctct 9780
 cctctcagga gccggcatca tggattcctt caaagtagtg ctggaggggc cagcaccttg 9840
 gggtctcccg ctgcaagggg gcaaggactt caatgtgccc ctctccattt cccgggtgag 9900
 cctaggtttg gggagggggc tccccagcg gtctttcgggt gcttaggtct ccagaggggtg 9960
 50 atggggggag tcctaacagg agctggtcag gggccagcag gccaggagat gtctaggtcc 10020
 ggagatgtag tggtagctgc ctgccacaag gactcccaat gaggtggata ctgggagggg 10080
 gcacccaggc ttctccagcc ctgcactgta cccgatgctg ttctcccaag ctctgtggc 10140
 cacctctgag ggctggaggg aggtcatttg tgcaggatgg gagcctaaca ttccaggagg 10200
 tatctaaact tgaggtggca atgcttggag ccaggcccca ggcaggacac tgtgactata 10260
 55 ggatttcact tcagcctcac tgccgcccag ggaatagcaa tctcatccc gtttttccag 10320

atgagagaag aactcatgga gaggtggcgg ggctcgctca tcgagtcctat ggtgaagcag 10380
 ggattggaat tgaggcacag catggcgtag atttttttgt ggtagaagggt gtctctcccc 10440
 agcctatgta aggaccaca tccactgttc ccattcagga tgtggtggcc tttgacccca 10500
 5 agcagaagtg taggacaggg ctccattcta ggggcttaac ttcagcttcc aagagcctgc 10560
 cctgggtgtg gtggagctgg aggctggctc ctccctgtag cagggggatt gccttataag 10620
 cccaagaatg cagccccacg ctgggatggc caacagtggc tgcggctctg agagctgaaa 10680
 agggctggcc taggcctggc cccctgaacc ccactggtgg gcctctcagc tggtcaccag 10740
 gctgcagctc cagctgtatg gtccagttgt gagacacaac aaattgcctg cccagagtgg 10800
 10 gtgagggcag cctgtcggct ggcatctctg actggcctgg gggtcaggag ggggtgggga 10860
 ctctctgccc ctatatccgc ctgccccgag agaccacccc aggcgcgggg tgggcaggca 10920
 gctgttgtca ggaagcccaa ggcaagccca gcctggaggg gccagaggg tcgtggcctg 10980
 aggaggggct caagctggag tctgtctgta ggagctgggc gtgggggtta ggggtggcag 11040
 gccagcagtg ctcttctcag gggctctttg atggcattct cctggaacct gccccgccag 11100
 15 cagggtagtg aggcagtggg tgccctatga cacacgtccc actacatagc cctcacacag 11160
 ccctgaaacc tacctgacgt cctgctccct gggaaagtgc tggcccagtg tgtctgggga 11220
 gcctgaacct cagtttcttc cctgatggag atgactttca gatatggcct gttgggggca 11280
 ctccgggctc cagctccctg gtcagcatcc ctggcatgtg ggccggggcca ctagctgac 11340
 ccagccctgg agttggacct gggcccacat ggggtgggtga ggtgggcttt tctgagttag 11400
 20 gccagcccc tccccctccc ctgacccag aatggaggga ggtgggagg gcaagggtg 11460
 gctgtgggccc caggcctggg agatgaggta acgtctggga ctggggggct gggctgctca 11520
 ggctgactca cccccacct atgcagggtc cagccccctg gctttttccc tcttgggttc 11580
 ctctggcctt accctgcccc tggcttgagc cctccctgc ctctctccag ccaccgccc 11640
 agcgtctgtc tctgtctccc tgctgccctc ccacgctct gaacaccct catcctctgt 11700
 gcttccctgc ctctcactc tgggaaggga agccgtcccc gccccccacc cctctccag 11760
 25 gagccagcta gctgcacccc aagacccca cctcgggctc agcccacagc tcccaggagc 11820
 cagccctgtg ggcagggagt ggctgggcca ggtttccctt ctactgactc accatgacct 11880
 tgagtaagtc acttccccctc tgggtgtgca ctccccata cacagtataa ggggttgatt 11940
 tagttggatt gaactaaagg tgaggagtg gctcagggtg tctccagggt ggctgacccc 12000
 tcagttgggc ccccatgctc agcagagggt gccacagtg gtggagcctt agggtcagag 12060
 30 aacttctctg gctctgcctc ttactagctg ggtgacttga ggcaagttgt ttaacctctc 12120
 tgtgtacatt tgcaagtgca aaatgggtaa aatcccagat tactccacaa ggttgttgga 12180
 agattcagtg tcaatatgta gcatagttgg tgctcaataa actgaagcaa gtcttcttat 12240
 ttagcgagtg aggaaggggc cgcgagctc tcttagcctt ctgacctcct acgcaagcaa 12300
 gaggtcatgt tgagcccagc tcgcctttct tttcccagtg ctgtcaagct ctgtgcctgg 12360
 35 ctgcccctgcc ctctgacatc tctctgaaac ctcttgctc cctctccct gcctcagctc 12420
 agtctgtgca ctgacccacc tgaggagcct cctggggcca ctggcagcct ggaccccccc 12480
 agatcccccc caccagtga aattgtcttc cagcactgcc tcacaaaagc ctacttgatg 12540
 cagtgccagg cctcttgcca gatggctggg tggctccctta ggcttgagc cagtcaacct 12600
 gccctgcctg tgttgctggg gctgggctag aggcctggaa ggggtttatc aggtcaccc 12660
 tctcagggcc tgggagatac ccaatcccag acattaaaac tgccagtagc cctctacct 12720
 40 tcaaagccaa gtcctgggtc ctccccctgg cattcaaagc catcgtaagt gaactctcac 12780
 ccgctaggca gcacacgcca ttctccttta ccgaggccca ccgcttctc aaagtcatte 12840
 ctgatggctc cagctcatgc tgggtggcagc catctctccc agcctactgt ctctactcat 12900
 tgccacagga accagggact cccagctcaa gagcctgaag gattgggggtc aggggaaatt 12960
 ggcagtcgag ggcttgggag tgacagccat gtatggccta cgaagtccca gctgtcaact 13020
 45 taggtcccat tcaggcagtg ttcacaggga accgggagat aacagggcct gttcctggct 13080
 ctcaaagggt cccagcagac ccctatagat ggcccccgac aggggtgctgg ggggtgagag 13140
 gtccataaga gccccgggtg gtttcgggga ggaagctgcc cctgcatgg gccagagggc 13200
 atatctggta ggtggagtgg cctgggcagg aggcagcag gagcctcaa aggcaatgg 13260
 cctcctgaaa cacttgggct ttagcctgag cgtggctgtt tgtggacatc atagcaattt 13320
 50 ctggactgtg ggggagggtg gtggcggtga atagataagc atcgtgactg gggagactca 13380
 ggtgagcacc acctgaggga gagggtctgg cagtgaataa ataagcagtg tgactgggaa 13440
 attgtgaagc ttgaatgaag agctctctgg gttctggaag tgggacagct ttgggtgggg 13500
 tagaactatg accgtcagcc tggcttgggt ctgcagggtc cagggcctcg gtcactttgc 13560
 cagtgttacc accgtcagcc tggcttgggt ctgcagggtc cagggcctcg gtcactttgc 13620
 55 ttctctctcc acagctcact cctgggggca aagcggcgca ggccggagtg gccgtgggtg 13680

EP 1 808 182 A1

actgggtgct gagcatcgat ggcgagaatg cgggtagcct cacacacatc gaagctcaga 13740
 acaagatccg ggcctgcggg gagcgctca gcctgggcct cagcaggatg gcgggtggac 13800
 atggatgggt gcgcccgccg tggcagtggg gatccctgcg gcccggccg ctgtcacgct 13860
 5 ttccttctcc tccaggggcc agccgggtca gagcaaaccg cagaaggtag gaggctggcc 13920
 gggacatccg ggcgggtggg ggtgtgggct tggacggcca ggctgtctcg cctcctggc 13980
 acattctcgg taccccaatc cctggccggg agtggagggc agaaaccgga gctaaggcgg 14040
 gtctagggcc ctggagttga gccaggggct gctgcacggc cctggcacca cgcattgtccg 14100
 cctgtctgtc cgcctgtctg tccgcctgct gcctcccgc gccggcgtg cgtgctcgc 14160
 10 cgcactcggg cagccctcgg tccgtcgtg actgagatcg ccactccaa atggggccct 14220
 tgaaacctga gtgtcctct ccccgtagcc tccaaataga ttaggggggt ggggtggggg 14280
 tggggggctg gagctgccgc tgtcctctgc tgcaggcgcc ccacttccac ccaggccccc 14340
 accttacct gcccgcccgc cctgccggc tgtgtctctg ccaggccctc cggcccccgc 14400
 gcggacctc cgcggtacac ctttgacccc agcgtctccc tcaacaagac ggcccgccct 14460
 15 ttgggcgccc ccggccgctg acagcgcccc gcagcagaat gggtagctcg gccctgccc 14520
 gcccgcgccc acgcatcag gccactgtg gccccacgcc cgtgcccgc tgtgtctcag 14580
 tctgtgtctg gccccagccc ggcggaaccg tgcggcacgc cccctggcgg ccgggggtggg 14640
 gctgcaggca caggggccct cccgaggtg tggcgccctg caggggaccg cctggggagg 14700
 ggtctctgaa tgacgccgag cccctgtctg gcggctgggg gttgggtgt ggtgtcgggc 14760
 20 cagctgagcc ccagacactc agtgccgct tgtcccggc tgttctgacc cctcccctc 14820
 tttcttctc tctgtgtct gtcccttctg cctttatct gtctgtctgt cttatttct 14880
 tcacagggtg agaccctga caagtctg agccccctc tgctgtgccc tttcttctc 14940
 cttttggcac tctgggtggc ggccctccc caccctggc gccctcctc ccactcgc 15000
 ctctgtctc tccactacc cggccagcag ggtcctggc ctcacctta ccactcct 15060
 cccatcactg taaccctaac ccacatgcac caaatcctg gaggggctgc cccaccgcc 15120
 25 caccctcagt gtgggggtct gagccacacc ctcccacag acagccgctc cgaccgctg 15180
 tcccagatgc cagcaagcag cggctgatg agaacacaga ggactggcgg ccgcccggc 15240
 ggacaggcca gtgcggtcc ttcgcatcc ttgcccacct cacaggcacc gagttcagta 15300
 agtgccagcc cagggcaggg ggtactttcc tgcccccag ccaggcgtg atccctgacc 15360
 ctgtgtcttt tttggtcaat gcctgcctct gctctctcag tgcaagaccc ggatgaggag 15420
 30 cacctgaaga aatcaaggta cagggaaggg caccagcccc tctcccacct cctgcctct 15480
 ccattccagc tactgcctg tgtctactcc tgaggctccc agctggggct ctcaattctc 15540
 ccttctctcc ttccttctct ccttctctcc ttccttctct ccttctctcc ttccttctct 15600
 ccttctctcc ttccttctct ctttctctcc ttccttctct ccttctctcc ccttctctcc 15660
 cctgcctccc ttccttctct ccttctctcc acttctctct ccttctctct ctgcccctca 15720
 35 gggaaaagta tgcctggag ctgcagagcc cagctacac ccgctccgg gactggcacc 15780
 accagcgctc tgcccagtg ctcaacgtg agtcgtagcc cggccctctc cagccggctg 15840
 ccctctctgc ctccctcttt ctgttctcc tgcccagggc acccccttag tgctccagc 15900
 ttctgcctac ctacccccc ctttctgccc cctggcctga gcctcctgt ggcctggccc 15960
 tggccgccc cctgggttca tctgacactg ccttccctct ttgcccgtg gtactgtgt 16020
 40 ctgcccaggtc tgtgtgtcct tgggcatgga ataaacatc tcagccctgc ttgtctgtcc 16080
 tgtctctctat ctttgtggac ctggtttgca tttggggtgt gggggtgttt cgtggttcgg 16140
 actgtttggg ccttgcctc cttgttttca gtgggagggg gtacctggca aaggggccct 16200
 gccctgccat cacagatggc ttcctggcat gaggggagcc ccaggagctg cctcagaagc 16260
 gggagccctg cctcgtctcc cagctagaga ccgacacca gctaactgga cattgtctagg 16320
 agaagctgcc ctcccatcc ctacccagc gggacctgga atccaactc gcagtttcca 16380
 45 cgccccagc catctcccgt gggccagca ggaccaggc tgggggggtg ggccatgtca 16440
 ggaagctcag ccattgcagg ccttgaatgg cagatcttgc agccagggtg ccaggacaga 16500
 agccccagcc ccagcctcat ctacacccca ggagccctg cctgggtgaga gggagtgggc 16560
 tcgggcctg gcaagggtg gcagcctcca ggggcatggg ggtgggtggc tctctcagc 16620
 tgctggggc tccacccccg tcccttggg tccctgggca cccctttaga gtcactttcc 16680
 50 ccggcaggcc ctaccgccc cagccctacc agccggcgc cctgggctgt ggaccctgcg 16740
 tttgcccagc gctatgcccc ggacaaaacg agcacagtgc tgaccgggca cagccagccg 16800
 gccacgccc cgcgctgca gagccgcacc tccattgtgc aggcagctgc cggaggggtg 16860
 ccaggagggg gcagcaacaa cggcaagact cccgtgtgtc accagtgcga caaggtcatc 16920
 cgggtgggtg cctgttctc tccgacctg ccttcccat cctgcagccc agccccacct 16980
 55 gtctgcccac ctgtcttgc tcagctgcga ctggggggaa taaggattca gtctcagct 17040

EP 1 808 182 A1

	ggagtaggag	tagggacctg	ggctgggtcc	tcccattctt	aatcccacgc	tacctacccc	17100
	agcccaccca	caacaactgc	tagcagcatc	tgccgtggcg	aaatagccga	agggccaacc	17160
5	ataggctgaa	gctgcacccc	tacctttgct	gctctctggg	caaagagggg	cctgccccct	17220
	cccagcggt	ctgccccctc	ctcctgctct	ctgtctccct	ctgctctcag	agcatacagg	17280
	cctggagcca	ctccccctgt	gcactgcccc	gtggggccaa	gcagcatcaa	acacccccca	17340
	gcatcagcgt	gccggattct	agagccttcc	taattcgtag	gcctggcctg	ctctcatctc	17400
	tgtcagctct	tttttttttt	tttttgaaac	agagtctcac	tgtgttgccc	acgttggcgt	17460
	gcagtggcgc	gatctcggct	cactgcaacc	tctgcctcct	gggttcaaga	gattctcctg	17520
10	cctcagcctc	ctgagtagct	gggattacag	gcacccgcca	ccatgcctgg	ctaattttgt	17580
	attttttagta	gagacggggt	tttaccatgt	tggccaggct	ggtctcaaac	tcctcacctc	17640
	aggatgatctc	aggcctgcct	tggcctccca	aagtgtggg	actacagggtg	tgagccactg	17700
	tgcccagccg	actctatcag	ctcttgccag	gtagaacagg	caggccagca	ggacagggca	17760
	gctccagggg	ttgcccaggg	gcggctcagc	ttttatgagg	ctccagtcgt	cagcccttcc	17820
15	tcccgggggc	ctccctgctc	taaagctgcc	tctcctgtca	ccagcagttc	agtgtggcgg	17880
	actggctctg	taagcttcat	ggctgccacg	gtcacttccc	aagcctgtct	tctatcctat	17940
	gtggaaaatg	gggagaatga	actgtccctc	ccaaggcctc	ctggtgggtg	gtcagtcaac	18000
	ctgaaggggg	ccaagacccc	cacctctctg	cgtgtgctcc	ctctgaccgc	tctcgccctc	18060
	ctgcaggggc	cgctacctgg	tggcgctggg	ccacgcgtac	cacccggagg	agtttgtgtg	18120
20	tagccagtgt	gggaaggctc	tgggaagagg	tggcttcttt	gaggagaagg	gcgccatctt	18180
	ctgccacca	tgctatgacg	tgcgctatgc	accagctgt	gccaagtga	agaagaagat	18240
	tacaggcgtg	agtagggctg	gctggcgggg	agggtggctc	aagcctgtca	gtgggaacga	18300
	gggtgtctgg	gaaaccacca	gtccaggtct	ctccccag	gagcctccgg	gtccttacca	18360
	gcgtataata	tgggctgctg	tactggcctc	accctgcatt	agtcaggatg	ctcttaacaa	18420
	atgaccatgt	tcctgtctcag	aaaccgcccc	aggctgcaaa	gagcaggagg	accaagccag	18480
25	gagaagccct	gggcctcctc	gactccact	ttgggtcttc	cctgccttgg	tgaaatgaca	18540
	gaacggccaa	cttgacacgc	tgaagctgct	ctgtctcatg	cgctctcttc	atctctggat	18600
	ccagagccag	ggctgccagg	agtagccaga	gagctctgtg	tggatgatgt	catattagtg	18660
	aggtttacct	tgaccacgag	cagtgggaaa	ctcaaaataa	tgggtggctta	tttctcatct	18720
	aaaaacatcc	cggggtgggt	ggctctgggac	tgatctggtg	gacccaggct	ccgccttggt	18780
30	gcttgactgt	tggcagcacc	tgcttactta	ccactcatgg	tgcaagatga	cacttcagcc	18840
	tccgcacaaa	tgctcacctt	ccagccagca	ggaagtccga	aggagaagaa	aggggacaga	18900
	gccccatggc	gtccatcctt	agaggatgct	gccacctgaa	cctctgcttt	catcctgttg	18960
	gtcagaaccc	agtcacatga	ccacaccag	tggcaacgga	ggctgggaaa	tatagtcttt	19020
	attttgggca	cccatgtgtc	cagcaaaact	gggggttcca	tcagtccgca	agaacgggag	19080
35	agtggccgat	gcagtggctg	atgcttgat	ccagcactt	tgggaggtcg	aggtgggagc	19140
	atcacctgag	gtcaggagtt	caagaccagc	ctggccaata	tgggtgaaac	ctgtctctac	19200
	taaaaataaa	aaaattagct	gggtgtgctg	gcgcacgtgt	agtcacagct	acttgggagg	19260
	ctgaggcagg	agaatcgctt	gatcttgaga	gggtggaggtt	gcagttagcc	aagattgtgc	19320
	cactgccttc	cagcctggga	gacagcaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaagggcc	19380
	aggcacgggtg	gctcacacct	gtaatcccag	cactttggga	ggccgagatg	ggcggtatcac	19440
40	gaggtcagga	gattgagacc	atcctggcta	acacggtgaa	accccatctc	tactaaaaat	19500
	acaaaaaaat	tggccgggca	tgggtggagta	gtcccagcta	ctcgggaggc	tgaggcagga	19560
	gaatggcgtg	aacctgggag	gcagagcttg	cagttagccg	agatcgcgcc	actgcactcc	19620
	agcctgggca	acagagcgag	actcttgtct	caaaaagaaa	aaaagaaaga	gaaatctgcc	19680
	tcccagcctt	gggctcctgc	cctaccagcc	cacaccctg	gtagagcctc	ctctcccacc	19740
45	agctcaaagc	ccaagtccct	tcactgtgac	cttgtctgct	cctctaaaac	aggcaacacc	19800
	agacagttag	aagagccagc	cagacatggg	cagaaaacct	atctctgtga	tctactggct	19860
	gtgtgagcag	gggctagtgt	ctctctctgg	gcctcactga	agagaagggg	ggcactatgc	19920
	tagggccggc	acggttgcaa	ggtagatgta	agatggggta	cagggtgtgt	ggagggcaga	19980
	aatgcaccat	ccgaaggcta	catgtccccc	acacttatgt	cttgcctggc	ccacactggt	20040
50	tcattttaaa	atcagtagca	aacaatttaa	aaaatcagaa	gatttgcttg	catgatgcag	20100
	tggctcatgc	ctgtaatccc	agcactttgg	gaggccaagg	tgggaggatt	gcttgagccc	20160
	aggagttaaa	gaccagcatg	ggcaccatag	caagacccct	gtttctacaa	aaaaaaaaaa	20220
	attagaaaaat	tagccaagtg	tgggtggcatg	cacctgtggt	cccagctact	tgggaggcag	20280
	agggaaaagt	agatctcctg	ctttttatgt	ctttatgtat	aatgataggg	tcttgcctctg	20340
55	ttgcccaggc	tggagtgcag	tggcatgac	actgtctcact	gcagccttga	tctcctgggc	20400

	tcagaggatc	ctcccacctc	agcctcccaa	atagctagga	ctagagggtgc	ccaccagcat	20460
	gctcagcaga	tttttaaatc	ttttttaga	gatgaggttt	tgctatgttg	cccaggctgg	20520
5	tctcgaactc	ctggcctcga	gcatcctcc	caccttggtc	tcccaaagca	ctgggattac	20580
	agacgtgagc	cactgcgccc	agcagatttc	tctttaacac	ctagatttca	gcctgagcca	20640
	ggcaggcatt	cctgaatgaa	ccagtagtac	tgctcccaga	agaagaggte	ctcctccgtg	20700
	tgacacagtc	cccacttggt	ccttgagggg	attggatctg	ggatccctgg	atttaaactc	20760
	agggccatcc	tcataacagc	ctcacagggt	tgggatttagc	ttcccagttc	acaagggaag	20820
10	aaaccaagac	ttgagaaggt	caaggtctgg	ccagaccac	acatcttgga	ccctcatacc	20880
	gcctcgaggg	cccatgctgc	cctctgcctg	ctccagatgt	gaatactgct	ggccctgggt	20940
	ggccccgggt	ggccccgagg	gtcctagggg	tgaacagccc	agcccaggga	gagctcagcc	21000
	ccttgctgct	ctgccccctc	ccacctcctg	cggaggccag	tcgactcacc	cacaaagggt	21060
	caggcactgt	ggggatagat	cagctaacaa	aacagttgat	gcttcctgcc	cttctgggtc	21120
	ttacattttg	gctggaagaa	gaggggagag	gcagactgta	agcaataagc	gcaataagta	21180
15	gggtgcctgg	aagtaatggt	agatcacgtt	acggaaaaca	ggaaagagca	gagcgacaag	21240
	tgctgggggt	cgtggtgcag	ggaaggcagc	tggctgctgc	tggtgtgggt	agagtggtgc	21300
	ctcatggaga	agactgcatt	cgagcagaaa	cttgaagggg	gtgaggggtg	agcctagaga	21360
	tatctggggc	agagcagtc	aggcagaggg	gacagccggt	gtcaagccca	ggacaggagt	21420
	gtgcctgggt	tgccagtttc	aggcaagagg	ccagtgtgca	gaggcaaggt	gagaacgcaa	21480
20	gggagagcag	tggcggagac	gggtgggaac	gaggtcagac	ctgctggcct	ccagcctctg	21540
	catggggcct	ggctcttgct	gggagcaatg	ggaagcagta	cacagtttca	tgcaggggga	21600
	gaaggcctgt	cttgggttgc	agggggcacgc	tgtggcagct	gggatcagag	agaggagctt	21660
	gtaggccagt	tggtatgtgg	tcccacgggc	cagatggcca	tggcttacct	cacttcagggt	21720
	aggctgtgag	aagcactcag	aatctggatg	tgcttggggg	gtgggcccc	ctggatttcc	21780
25	tgggtggacct	ggtgtggggg	gtgagaggag	ggtgtgtttg	gctgcagcag	acaggagaat	21840
	ggagttgcca	tccgcgtgat	ggggatggct	gtgggaggag	aggtttgggg	tgagggaatc	21900
	aggaactgag	tgctggacat	ggcaagtctg	aaggcgcagt	ggtcgtccac	tcagagacct	21960
	tggagttgga	gatggagggt	tgggagtcct	gaacagttag	atgtagtgtt	taccgcgaga	22020
	aggaacaggg	cttgccggcca	gcccctcctgt	gttcccgtga	cccagggcag	ggcagagggt	22080
30	gcctgagcct	gcccagtgac	tgggacctcc	ttccaggaga	tcattgcacgc	cctgaagatg	22140
	acctggcacg	tgactgctt	tacctgtgct	gcctgcaaga	cgcccatccg	gaacaggggc	22200
	ttctacatgg	aggagggcgt	gccctattgc	gagcgaggta	cccactggcc	agtgaggggt	22260
	aggagggatg	gtgcatgggg	caggcatgaa	tccaggctct	ctttctctct	gccccatttc	22320
	tcagactatg	agaagatggt	tggcacgaaa	tgccatggct	gtgacttcaa	gatcgacgct	22380
	ggggaccgct	tcctggaggg	cctgggcttc	agctggcatg	acacctgctt	cgtctgtgct	22440
35	gtgagagccc	cgcccctcga	actgagcccc	aagccaccg	gcccctctgt	cattccccag	22500
	gagatgcagg	agaagtggg	aaggggcctc	tcctgctgcc	cccaacccca	tgtgactggg	22560
	cctttgctgt	ccttagatat	gtcagatcaa	cctggaagga	aagaccttct	actccaagaa	22620
	ggacaggcct	ctctgcaaga	gccatgcctt	ctctcatgtg	tgagcccctt	ctgcccacag	22680
	ctgcccgggt	ggcccctagc	ctgagggggc	tggagtctgt	gcccctgcatt	tctgggtagg	22740
40	gctggcaatg	gttgccctaa	ccctggctcc	tggcccagag	ctggggctcc	ctgggcccctg	22800
	ccccaccac	cttatcctcc	caccccactc	cctccaccac	cacagcacac	cgatgctggc	22860
	cacaccagcc	ccctttcacc	tccagtggca	caataaacct	gtaccagct	gtgtcttgtg	22920
	tgcccttccc	ctgtgcatcc	ggaggggcag	aatttgaggc	acgtggcagg	gtggagagta	22980
	agatggtttt	cttgggctgg	ccatctgggt	ggtcctctgt	atgcagacat	ggcgggctca	23040
45	tggttagtgg	aggaggtaca	ggcgagaccc	catgtgccag	gcccgggtgc	cacagacatg	23100
	aggggagcca	ctggtctggc	ctggcttgga	ggttagagaa	gggtagttag	gaagggtagt	23160
	tagcatgggt	gctcatgcct	gtgatcccag	cactttggaa	ggccaagggt	ggcagatcgc	23220
	ttgaggtcag	gagttcgaga	cctcatggcc	aacacgggtg	aacagcgtct	ctagtaaaaa	23280
	tacaaaaatt	agccgagtgt	ggtggggcat	gcctgtaatc	ccagccactc	aggaggctga	23340
	ggcgggaaaa	tcacttgaac	ctgggaagtg	gaggttgcag	tgagctgaga	tcacaccact	23400
50	gcgcgcgagc	ctgggtggca	gatggcagag	cgagaccctg	cttcaaaaaa	aaaaaaaaaa	23460
	aaaaaaaaaa	gaagggtagt	tgtagtggg	ggtggatctg	cagagatatg	gtgtggaaaa	23520
	cagcaatggc	cacagcaaag	tcctggagg	gccagctgcc	gtccaaacag	aagaaggcag	23580
	ggctggagag	ggtagccctt	aggtcctggg	aagccacgag	tgccaggcag	tagagctggg	23640
	gctgtctctt	gaggttaggg	cagggcaagg	cacagcagag	tttgaaatag	gtttgtgttg	23700
55	tattgcagaa	aagaggcccc	agaacactga	gggagtgcag	gagggagggt	gggaggagga	23760

gttgcagcag ggccctagggg cggggggccag gcaagggagg ggcagagagt aatatggcag 23820
 agatgggacc cagtggcagg tccgggggat gagggatgga gagaaggaca ggagcgttgc 23880
 caggcatctg gcctatacca gacatgctca cgctgtctcc cgcgaaacct ctagcaacct 23940
 5 tgcgcggttg tctgcaatca cttatttcat tttttctttt ttaactttaa ttttttttgt 24000
 ttttaagaga caggatctcc ctagggtgcc cgggctgggt tcaaactcct gggtcaagc 24060
 aattcttcc ccttagcccc aaagtgtctg cattacaggt gtgagccacc atgcctggcc 24120
 cacttatttt ctagatgagg cacagaaaga ttgggagact tgaccaaggt cacgctgtca 24180
 ttgagccatg agccagacta gaatccaggc ctgaagctgg gtgcgctgtc ccaggactgg 24240
 10 ctggcactga gtaccatttg ccagcgagca tctctctggg aagctgactt ctgcccggta 24300
 cctggaggac tgtagacctt ggtggtggcg ccgtcactct ggggcttcct gcctccact 24360
 gatgcccgca ccaccctaga gggactgtca tctctcctgt cccaagcctg gactggaaag 24420
 actgaagaga agccttaagt aggccaggac agctcagtgt gccatggctg cccgtccttc 24480
 agtgggtccct ggcatgagga cctgcaacac atctgttagt cttctcaaca ggcccttggc 24540
 ccggtcccct ttaagagacg agaagggctg ggcacgggtga ctcacacctc taatcccagc 24600
 15 actttggaag gctgaggctg gagaagggtc ccagcttagg agttcaggac cagcctgggc 24660
 aacatgggtga gacctgttt tgttttgttt tttgtttttt tgagatggag tcttgctctg 24720
 tcgcccaggc tggagtgcag 24740

<210> 42
 <211> 25
 <212> DNA
 <213> Rattus norvegicus

<400> 42
 gcactacctt gaaggaatcc atggt 25

Claims

1. An isolated nucleic acid molecule comprising a SEQ ID NO: 37 or SEQ ID NO: 39.
2. An isolated human LMP protein encoded by SEQ ID NO: 37 or SEQ ID NO: 39.
3. A vector comprising the isolated nucleic acid molecule of claims 1.
4. A host cell comprising the vector of claim 3.
5. The host cell of claim 4, wherein the host cell is selected from the group consisting of prokaryotic cells, yeast cells and mammalian cells
6. The isolated nucleic acid molecule of claim 1, further comprising a label.
7. A human LIM mineralization protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 38 and SEQ ID NO: 40.
8. A monoclonal antibody specific for a HLMP-2 (SEQ ID NO: 38) or HLMP-3 (SEQ ID NO: 40).
9. A method of inducing bone formation comprising transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 39.
10. The method of claim 9, wherein the isolated nucleic acid molecule is in a vector.
11. The method of claim 10, wherein the vector is an expression vector.
12. The method of claim 11, wherein the vector is a plasmid.

13. The method of claim 11, wherein the vector is a virus.

14. The method of claim 13, wherein the virus is an adenovirus

5 15. The method of claim 13, wherein the virus is a retrovirus.

16. The method of claim 9, wherein the osteogenic precursor cells or peripheral blood leukocytes are transfected *ex vivo*.

10 17. The method of claim 9, wherein the osteogenic precursor cells are transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

18. The method of claim 9, wherein the LIM mineralization protein is HLMP-3 (SEQ ID NO: 40).

15 19. A method of fusing a spine, comprising:

- (a) transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 39;
- (b) admixing the transfected osteogenic precursor cells or peripheral blood leukocytes with a matrix; and
- (c) contacting the matrix with the spine;

20

wherein expression of the nucleotide sequence causes mineralized bone formation in the matrix.

20. The method of claim 19, wherein the osteogenic precursor cells or peripheral blood cells are transfected *ex vivo*.

25 21. A method of inducing systemic bone formation in a mammalian host in need thereof, comprising:

- a) transfecting osteogenic precursor cells or peripheral blood leukocytes with a vector that is stably maintained in the osteogenic precursor cells or peripheral blood leukocytes, the vector comprising SEQ ID NO: 39 operably linked to a regulatable promoter, wherein the regulatable promoter responds to an exogenous control compound; and
- (b) administering to the host, as needed, an amount of the exogenous control substance effective to cause expression of SEQ ID NO: 39.

30

22. A method of stimulating production of an osteogenic soluble factor by an osteogenic cell, comprising:

35

- (a) transfecting the osteogenic cell or peripheral blood leukocyte with an isolated nucleic acid molecule comprising SEQ ID NO: 39; and
- (b) overexpressing the isolated nucleic acid molecule.

40

23. An osteogenic soluble factor produced by the method of claim 22.

24. The osteogenic soluble factor of claim 23, wherein the osteogenic factor is a protein.

45 25. A method of inhibiting the expression of HLMP-2 or HLMP-3 comprising transfecting a cell wherein HLMP-2 or HLMP-3 is expressed with an antisense oligonucleotide.

26. The method of claim of claim 17, wherein the isolated nucleic acid molecule is in a vector selected from the group consisting of a plasmid and a virus.

50

27. The method of claim 26, wherein the vector is a plasmid, which plasmid is directly injected into muscle tissue.

28. A method of inhibiting bone formation comprising transfecting osteogenic precursor cells or peripheral blood leukocytes with an isolated nucleic acid molecule comprising SEQ ID NO: 37.

55

29. The method of claim 28, wherein the isolated nucleic acid molecule is in a vector.

30. The method of claim 29, wherein the vector is an expression vector.

31. The method of claim 30, wherein the vector is a plasmid.

32. The method of claim 30, wherein the vector is a virus.

5 33. The method of claim 32, wherein the virus is an adenovirus

34. The method of claim 32, wherein the virus is a retrovirus.

10 35. The method of claim 28, wherein the osteogenic precursor cells or peripheral blood leukocytes are transfected *ex vivo*.

36. The method of claim 28, wherein the osteogenic precursor cells are transfected *in vivo* by direct injection of the isolated nucleic acid molecule.

15 37. The method of claim 28, wherein the LIM mineralization protein is HLMP-2 (SEQ ID NO: 38).

20

25

30

35

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 07 00 3497 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	WO 99/06563 A (UNIV EMORY) 11 February 1999 (1999-02-11) pages 7-16, examples 1-28, claims 1, 8-98, 11, 13, 6, 23, 30-31, 38 * the whole document *	1-37	INV. A61K48/00 C07H21/04 C07K14/00 C07K16/00 C12N15/63 C12N15/85 C12N15/86
Y	LIU Y ET AL: "BMP6 induces a novel LIM protein involved in bone mineralisation and osteocalcin secretion" JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 12, 1 August 1997 (1997-08-01), page 49, XP002083263 ISSN: 0884-0431 * the whole document *	1-37	
			TECHNICAL FIELDS SEARCHED (IPC)
			C07K
INCOMPLETE SEARCH			
The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search		Date of completion of the search	Examiner
Munich		2 May 2007	Vix, Olivier
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

1
EPO FORM 1503 03.82 (P04C07)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 07 00 3497

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (IPC)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P,X	VIGGESWARAPU M ET AL: "ADENOVIRAL DELIVERY OF LIM MINERALIZATION PROTEIN-1 INDUCES NEW-BONE FORMATION IN VITRO AND IN VIVO" JOURNAL OF BONE AND JOINT SURGERY, JOURNAL OF BONE AND JOINT SURGERY. BOSTON, US, vol. 83A, no. 3, March 2001 (2001-03), pages 364-376, XP009013151 ISSN: 0021-9355 * the whole document * -----	1-37	
			TECHNICAL FIELDS SEARCHED (IPC)



Although claims 9-19 and 21 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 07 00 3497

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

02-05-2007

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9906563 A	11-02-1999	AU 745122 B2	14-03-2002
		AU 8602998 A	22-02-1999
		CA 2297489 A1	11-02-1999
		EP 1007673 A1	14-06-2000
		JP 2001512019 T	21-08-2001
		TW 244502 B	01-12-2005

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 4800159 A, Mullis [0030]
- US 5580775 A, Freneau [0038]
- US 5504192 A [0080]

Non-patent literature cited in the description

- **B. L. HOGAN.** *Genes & Develop.*, 1996, vol. 10, 1580 [0002]
- **D. M. KINGSLEY.** *Trends Genet.*, 1994, vol. 10, 16 [0002]
- **BODEN et al.** *Endocrinology*, 1996, vol. 137, 3401 [0003]
- **BODEN et al.** *Endocrinology*, 1997, vol. 138, 2920 [0003]
- **BAUMGARTNER et al.** *Circulation*, 1998, vol. 97 (12), 1114-23 [0024]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Press, 1988 [0029]
- **DAVIS et al.** *Basic Methods in Molecular Biology.* Elsevier, 1986 [0029]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology.* Wiley Interscience, 1988 [0029] [0074]
- **GRAHAM ; VAN DER.** *Virology*, 1973, vol. 52, 456 [0035]
- **KIMURA et al.** *Virology*, 1972, vol. 49, 394 [0036]
- **SOMPAYRAC et al.** *Proc. Natl. Acad. Sci. USA*, 1981, vol. 78, 7575 [0036]
- **POTTER.** *Proc. Natl. Acad. Sci. USA*, 1984, vol. 81, 7161 [0036]
- **GODDIN et al.** *Molec. Cell.-Biol.*, 1981, vol. 1, 743 [0036]
- **SOUTHERN, E. M.** *J. Mol. Biol.*, 1975, vol. 98, 503 [0038]
- **ALWINE et al.** *Meth. Enzymol.*, 1979, vol. 68, 220 [0038]
- **SAMBROOK et al.** *Molecular Cloning: A laboratory Manual.* Cold Spring Harbor Press, 1989, 7.19-7.50 [0038]
- **AUSUBEL et al.** *Current Protocols in Molecular Biology.* John Wiley and Sons, 1987 [0041]
- **KOHLER ; MILSTEIN.** *Nature*, 1975, vol. 256, 495-97 [0042]
- Soft Agar Techniques. **MACPHERSON.** *Tissue Culture Methods and Applications.* Academic Press, 1973 [0044]
- **HARLOW et al.** *Antibodies: A Laboratory Manual.* Cold Spring Laboratory, 1988 [0044]
- **BODEN et al.** *Endocrinology*, 1996, vol. 137 (8), 3401-07 [0056] [0060]
- **NANES et al.** *Endocrinology*, 1990, vol. 127, 588 [0061]
- **SAMBROOK et al.** *Molecular Cloning: a Laboratory Manual.* Cold Spring Harbor Press, 1989 [0066]
- **CONNER et al.** *Proc. Natl. Acad. Sci. USA*, 1983, vol. 88, 278 [0071]
- The Analysis of Variance. **D. V. HUNTSBERGER.** *Elements of Statistical Variance.* Allyn & Bacon Inc, 1977, 298-330 [0085]
- **ENGLAND et al.** *Biochim. Biophys. Acta*, 1980, vol. 623, 171 [0086]
- **TIMMER et al.** *J. Biol. Chem.*, 1993, vol. 268, 24863 [0086]
- **HAIR et al.** *Leukemia Research*, 1996, vol. 20, 1 [0087]
- **TOWBIN et al.** *Proc. Natl. Acad. Sci. USA*, 1979, vol. 76, 4350 [0087]
- **SAMBROOK et al.** *Molecular Cloning: A Laboratory Manual.* Cold Spring Harbor Laboratory Press, 1989, 19 [0089]
- **BODEN et al.** *Endocrinology*, 1997, vol. 138, 2820-28 [0089] [0091]
- Quantitation of rare DNAs by the polymerase chain reaction. **AUSUBEL et al.** *Current Protocols in Molecular Biology.* Wiley & Sons, 1990 [0091]
- **CHENCHIK et al.** *CLONTECHniques*, 1995, vol. X, 5 [0100]
- **BORSON et al.** *PC Methods Applic.*, 1993, vol. 2, 144 [0100]
- **GUBLER et al.** *Gene*, 1983, vol. 25, 263 [0100]